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Abstract 
 
I was introduced to systems and computational biology as an undergraduate at the University of Virginia. 
In pursuing projects both for independent and thesis research, I was fascinated by the potential of 
mathematics and computers to describe complex phenomena in biology and to help address challenges 
otherwise intractable with traditional experimental methods. Continuing in this field for my graduate 
research allowed me to focus more heavily on problems in human health and disease, while building a 
diverse skill set that can also be applied to studying basic biology or even microbes for industrial 
applications. In my Ph.D. research, I have been a part of cutting-edge computational and systems biology 
endeavors with Nathan Price at the University of Illinois and, most recently, the Institute for Systems 
Biology. My work has focused largely on modeling biological networks—using both statistical and 
mechanistic modeling approaches—with applications to medicine, energy, and genomic science.  
 
The more coarse-grained of these approaches use statistical analysis of high-throughput expression data to 
identify molecular signatures of disease phenotypes; such signatures are indicative of aberrant function of 
genes or pathways. As a primary focus of my Ph.D. work, I have generated and applied tools to harness 
high-throughput transcriptomic data to identify molecular signatures—particularly a special class of 
signatures that quantifies the relative expression levels among multiple genes—and to help elucidate 
underlying mechanism of complex biological processes and properties. I have used both gene- and 
network-based signatures to pioneer approaches for predicting clinical phenotypes and outcomes of 
patient samples. Most notably, I led the development and implementation of a computational method for 
identifying biomolecular pathways (e.g., metabolic or signaling) that are perturbed in disease data. I used 
this method (described in Chapter 4) to identify differentially regulated and variably expressed pathways 
in a number of human diseases, and later investigated behavior-associated modules in a transcriptional 
regulatory network of the honeybee brain.  
 
As a more functionally grounded complement to statistical approaches, stoichiometric models of 
biochemical reaction networks can be used to simulate disease systems in mechanistic detail. I have 
developed an extensive background in constraint-based analysis of biochemical reaction networks, 
beginning with my contribution to the genome-scale reconstruction of the pathogen Leishmania major, 
while working as an undergraduate researcher. Building off of the metabolic and modeling expertise I 
gained through this project—as well as the construction of major signaling pathways in yeast—I was able 
to help substantially in the metabolic reconstruction of the butanol producing bacteria Clostridium 
beijerinckii when I began my Ph.D. at the University of Illinois. This model is now being used to identify 
genetic modifications that may lead to increased butanol production for industrial bioenergy applications.  
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Most recently, I have helped to pioneer and automate novel network reconstruction and modeling 
approaches in human tissues and cell types. In particular, I have applied these methods to reconstruct and 
validate the first genome-scale metabolic model for the deadly brain cancer, glioblastoma multiforme. 
This model and others like it will be transformative for mapping the genome-to-phenotype relationship in 
complex diseases to elucidate underlying mechanisms and pave the way for new therapeutic strategies. 
Moreover, the reconstruction and analysis of this model represents a culmination of the array of 
mechanistic and statistical approaches used and described over the course of my Ph.D. Perturbed 
metabolic pathways identified by statistical tools represent robust differences between healthy and 
diseased states, and in turn, serve as focal points for ongoing model simulation and development. 
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Chapter 1. Introduction and Overview1 
 
Monumental advances in molecular and cellular biology—beginning in the latter half the 20th century and 
continuing today—have provided an increasingly detailed portrait of human biology from the molecular 
to physiological levels. These advances have centered on “reductionist” experimental approaches aiming 
to annotate a vast array of biological components, from cells and tissues to genes and proteins. 
Collectively, these components represent a “parts list” for biological systems (e.g., biochemical pathways, 
larger interaction networks). At scales beyond a handful of interacting components, however, simple 
analysis techniques can become limited in providing comprehensible insight into resulting phenotypic 
behaviors. Systems biology is a rapidly growing discipline that employs an integrative approach to 
characterize biological systems, in which interactions among all components in a system are described 
mathematically to establish a computable model. These in silico models—which complement traditional 
in vivo animal models—can be simulated to quantitatively study the emergent behavior of a system of 
interacting components. Model development in the systems biology paradigm is enabled by the 
description of parts and interactions from reductionist biology, and also depends upon quantitative 
measurements. The advent of high-throughput experimental tools has allowed for the simultaneous 
measurement of thousands of biomolecules, paving the way for in silico model construction of 
increasingly large and diverse biological systems. Integrating heterogeneous dynamic data into 
quantitative predictive models holds great promise to significantly increase our ability to understand and 
rationally intervene in disease-perturbed biological systems. This promise—particularly with regards to 
personalized medicine and medical intervention—has motivated the development of new methods for 
systems analysis of human biology and disease. 
 
Herein, I present new systems biology tools and methodologies to explore perturbed molecular networks 
in disease. These methods collectively aim to identify informative changes that give rise to disease, which 
in turn could be leveraged to improve clinical diagnosis or even guide the development of novel 
therapeutics. Importantly, my work has included both statistical and mechanistic approaches to modeling 
large, often genome-scale biological information or data. The predominant focus, both in the development 
and application of the tools described here has been human cancers; among these, the brain cancer 
glioblastoma multiforme is the central focus of metabolic modeling efforts. The goal of this chapter is to 
provide a high-level introduction to the central topics and themes, around which the majority of the work 
                                                     
1 This chapter includes material that was reproduced with permission from the following publication: Edelman, L.B., 
J.A. Eddy, and N.D. Price. 2010. In silico models of cancer. Wiley Interdisciplinary Reviews: Systems Biology and 
Medicine. 2(4):438-459. (Cancer Complexity & Systems Biology section; text was collaboratively written with 
Luke Edelman).  
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described in this dissertation is based. Moreover, I have provided an overview of the chapters that follow 
to serve as a sort of roadmap for interested readers. 
 
 
Cancer Complexity & Systems Biology 
 
Cancer is an intrinsically complex and heterogeneous disease, making it particularly amenable to systems 
biology approaches. Malignant tumors develop as a function of multiple biological interactions and 
events, both in the molecular domain among individual genes and proteins, and at the cellular and 
physiological levels between functionally diverse somatic cells and tissues [1] (Figure 1.1). At the 
molecular level, genetic lesions interact synergistically to evade tumor suppression pathways, with no 
single mutation typically sufficient to cause transformation [2-6]. Beyond genetic mutations, transformed 
cells can exhibit changes in expression of hundreds to thousands of genes and proteins [7-9]. Genetic 
modifications observed in cancer are often accompanied by changes at the epigenetic level [10-15]. The 
convolution of genetic effects and epigenetic modifications illustrates the complex, nonlinear relationship 
between molecular state and cellular cancer phenotype, emphasizing the need for heterogeneous data 
integration through in silico models. The diversity of cancer models mirrors the broad array of molecular 
and physiological events characteristic of the disease (Figure 1.2). The most course-grained approaches 
use statistical analysis of high-throughput expression data to identify molecular signatures of cancer 
phenotypes. Such signatures are indicative of aberrant function of genes or pathways, and can be used to 
predict the type, stage, or grade of biopsied tumor samples. More advanced methods aim to statistically 
infer the structure and/or quantitative relationships among biomolecules within interaction and regulatory 
networks of importance in cancer. Alternatively, stoichiometric or kinetic models of biochemical reaction 
networks—constructed in a bottom-up, annotation-based manner—can be used to simulate in mechanistic 
detail the behavior of metabolism or signal transduction in cancer. 
 
The complexity of intracellular phenomena observed in cancer is mirrored by equally intricate 
interactions between cells and across somatic tissues. Among the most important biological systems 
mediating cancer development is the local tumor microenvironment—a complex, interacting system of 
cells and extracellular moieties. Contributory agents include the extracellular matrix [16], cooperating 
tumor and proximate “host” cells [17-20], extracellular signaling factors [21-23], and the metabolic 
context of local tissue [24, 25]. Other important agents include the infiltrating leukocytes and cytokines of 
the immune system [26-28]. Human cancers also exhibit other major interactions with somatic tissues 
concomitant to malignant invasion, such as tumor-induced angiogenesis [29-31]. The potential response 
to chemotherapeutics, radiotherapy, and surgical procedures represent additional confounding factors in 
the cellular and physiological behavior of cancer cells [32-35]. The heterogeneous nature of the tumor 
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microenvironment poses substantial modeling challenges, yet ongoing research has sought to characterize 
these cancer systems, including continuum and discrete models. 
 
Despite significant experimental and analytic challenges arising from cancer’s complexity, modeling has 
already successfully led to insights into cancer biology and treatment, as will be discussed in Chapter 2. 
Some of the earliest models describing the molecular basis of cancer over half a century ago implicated 
the absolute number of genetic mutations as causative for malignancy [36]. Today, important efforts in 
sequencing the human genome [37, 38] and now individual cancers [39, 40] mean that malignant genetic 
transformations can be studied and modeled in the context of the entire genome. 
 
 
Biological Networks & Cancer Metabolism 
 
Reconstructing detailed in silico models of biochemical reaction networks (e.g., metabolic, signaling, 
regulatory) at the genome scale establishes a platform on which different genetic perturbations can be 
related to emergent malignant functions and phenotypes. Metabolism, in particular, is arguably the best 
understood cellular process and is highly perturbed in oncogenesis, where cancer cells have increased 
metabolic rate to provide the energy needed for increased proliferation [41-43]. Metabolite-based 
analyses to probe cancer have been performed since the 1980s [44] and have shown that cancer cells 
display distinct metabolic profiles, which can be characterized to diagnose the type and progression of 
disease, inform prognosis, and assess efficacy of therapy [45]. Metabolic phenotypes that remain 
consistent across cancer types reflect decreased aerobic respiration activity [46, 47] coupled with 
increased glycolysis [45, 46] and increased phospholipid production [46, 48]. These observations have led 
to targeted diagnosis and treatment strategies [45, 49]. Based on past advances resulting from metabolite 
analysis in cancer cells, accurate profiling of the cancer cell metabolome—and integrating this data into 
cell-scale metabolic models—is of high interest. Doing so should not only further elucidate the 
pathophysiolgy of cancer, but has potential to improve methods of diagnosis and treatment.  
  
The most basic mathematical representation of a biochemical reaction network is a stoichiometric model, 
which describes the interconversion of biomolecules purely in terms of the number of reactants and 
products participating in each reaction. The generation of stoichiometric models and analysis of their 
properties is a well-established process [50-52], and genome-scale models of metabolism have been 
completed for a diverse range of organisms, including the prokaryote E. coli [53], archaea [54], and 
eukaryotes such as S. cerevisiae [55] and the protozoan L. major [56]. The reconstruction of a 
biochemical reaction network results in a database of stoichiometric equations that can be represented 
mathematically to form the foundation of a genome-scale, computable model. Computational tools for 
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constraint-based analysis (Figure 1.3) are then used to interrogate the properties of the reconstructed 
network in silico and to facilitate model-driven validation and refinement [57]. That is, physico-chemical 
and environmental constraints under which the network operates are applied in the form of balances, 
including mass, energy, and charge, and bounds, such as flux capacities and thermodynamic constraints 
[57, 58]. The statement of constraints defines a solution space comprising all non-excluded network 
states, thereby describing possible functions or allowable phenotypes. These methods are now being 
adapted for modeling human systems in greater detail. Genome-scale models have been used for 
applications ranging from biofuel production to drug target discovery [59, 60]. 
 
 
Dissertation Aim & Organization 
 
The overarching goals of the work presented in this dissertation were to (i) develop computational tools 
and frameworks to quantify molecular changes in biological networks that are either causal for or 
reflective of disease; and (ii) explore the application of these tools—particularly those related to network 
expression analysis or mechanistic modeling of cellular metabolism—to identifying perturbed systems in 
cancer.  
 
Throughout my Ph.D., I have had many opportunities to interact and collaborate with other scientists—
including students, post-doctoral fellows, and faculty; this has both enriched my own projects and 
allowed me to contribute in both intellectual and hands-on facets to the work of others. As such, the voice 
in subsequent chapters is sometimes more fluid to best indicate the origin of methods, analyses, results, 
and the text describing them. As much as possible, I have used first-person singular to clarify the projects 
or tasks for which I was directly responsible. In some cases, I use “we” when referring to more 
collaborative efforts; and of course, I gladly cite my colleagues when describing their specific 
contributions.  
 
The chapters in this dissertation can be briefly summarized as follows: 
 
Chapter 1 introduces the central themes and topics for the work described in subsequent chapters. 
Chapter 2 provides an introduction to and extensive overview of computational and systems biology 
approaches to modeling and investigating cancer. 
Chapter 3 describes a particular class of statistical models, Relative Expression Analysis algorithms, 
and reviews their potential as well as previously demonstrated applications in aiding cancer diagnosis 
and prognosis. 
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Chapter 4 presents a novel method, Differential Rank Conservation (DIRAC), which I developed to 
quantify patterns of gene expression in disease on the level of biological networks. 
Chapter 5 highlights several other applications of DIRAC (including in the honeybee and mouse 
brain), extensions of the method, and alternative gene- and network-based expression analysis 
approaches. 
Chapter 6 describes the construction and analysis of a genome-scale metabolic network for the 
glioblastoma multiforme cell line, U87 MG, a more mechanistic approach to network analysis 
compared to the statistical tools described in Chapters 3, 4, and 5. 
Chapter 7 offers a summary and conclusion for the ideas and work presented here as well as a 
prospective contemplation about ongoing challenges and future directions of my work and the field of 
systems biology. 
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Chapter 1 Figures 
 
 
 
Figure 1.1. Molecular and physiological complexity in cancer. 
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Figure 1.2. Biological scales and potential modeling approaches. 
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Figure 1.3. Schematic overview of constraint-based modeling. 
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Chapter 2. In silico models of cancer2 
 
Cancer is a complex disease that involves multiple types of biological interactions across diverse 
physical, temporal, and biological scales. This complexity presents substantial challenges for the 
characterization of cancer biology and motivates the study of cancer in the context of molecular, cellular, 
and physiological systems. Computational models of cancer are being developed to aid both biological 
discovery and clinical medicine. The development of these in silico models is facilitated by rapidly 
advancing experimental and analytical tools that generate information-rich, high-throughput biological 
data. Statistical models of cancer at the genomic, transcriptomic, and pathway levels have proven 
effective in developing diagnostic and prognostic molecular signatures, as well as in identifying perturbed 
pathways. Statistically inferred network models can prove useful in settings where data overfitting can be 
avoided and provide an important means for biological discovery. Mechanistically-based signaling and 
metabolic models that apply a priori knowledge of biochemical processes derived from experiments can 
also be reconstructed where data are available and can provide insight and predictive ability regarding the 
dynamical behavior of these systems. At longer length scales, continuum and agent-based models of the 
tumor microenvironment and other tissue-level interactions enable modeling of cancer cell populations 
and tumor progression. Even though cancer has been among the most-studied human diseases using 
systems approaches, significant challenges remain before the enormous potential of in silico cancer 
biology can be fully realized. 
 
In this chapter, I describe key examples of recent in silico modeling efforts in cancer. These include (i) 
statistical models of cancer, such as molecular signatures of perturbed genes and molecular pathways, and 
statistically inferred reaction networks; (ii) models that represent biochemical, metabolic, and signaling 
reaction networks important in oncogenesis, including constraint-based and dynamic approaches for the 
reconstruction of such networks; and (iii) continuum and agent-based models of the tumor 
microenvironment and tissue-level interactions. Finally, I examine the direction of ongoing research in 
cancer systems biology, and discuss opportunities for fundamental biological insights and their potential 
application to clinical practice. 
 
 
Enabling Tools and Technology in Systems Cancer Modeling 
 
With the initial sequencing of the Human Genome completed at the turn of the millennium, biological 
inquiry has been transformed by the ability to examine diverse cellular phenotypes such as cancer at the 
                                                     
2 This chapter includes material that was reproduced with permission from the following publication: Edelman, 
L.B., J.A. Eddy, and N.D. Price. 2010. In silico models of cancer. Wiley Interdisciplinary Reviews: Systems 
Biology and Medicine. 2(4):438-459. (all sections; text was collaboratively written with Luke Edelman). 
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genome scale. Experimental tools for measurement of the cancer genome, transcriptome, and proteome 
are being continuously improved, including microarray platforms [61-63], next-generation sequencing 
technologies [64, 65], and advanced mass spectrometry [66-68]. These tools for the high-throughput 
interrogation of cancer biology have developed in conjunction with analytical and computer-based tools 
for integration and annotation of the data generated. Together, these parallel advancements are enabling 
increasingly sophisticated models of cancer at the molecular and cellular levels.  
 
Software and Database Resources for Cancer Systems Biology 
 
With the rapid advancement of technologies for high-throughput biological measurement, the 
construction of tools for the distribution, integration, and assessment of this raw information has become 
increasingly important [69]. Multiple online databases (Table 2.1) have been created for the storage and 
distribution of genome-scale data, including transcriptomics [70, 71], regulatory sequences [72, 73], and 
proteomics [74]. Importantly, these resources provide easily accessible high-throughput data by which 
cancer models can be constructed and validated. This access enables the global study of disease in a 
manner not previously possible and will continue to be transformative for systems biology and systems 
medicine. Models of cancer at different scales of size and complexity often employ a priori biological 
information as constraints to impose parsimony on model architecture. Other web-based services provide 
annotation of both individual genetic elements [75-79] and their collective associations within distinct 
biochemical pathways or functional modules [80-85]. Additionally, published mathematical models and 
required parameters (e.g., reaction kinetics) can be obtained for diverse biological systems [86-88]. 
Among the major challenges for both statistical and biochemical cancer modeling is knowledge of protein 
interactions [89]. Multiple public repositories of human and cancer protein interaction networks are 
currently available based on yeast-two-hybrid data and other experimental methods [90-93]. Additionally, 
standardized markup languages for biochemical and signaling networks [94-97], as well as software 
packages [98, 99] have been developed to enable rapid porting of diverse datasets, annotations, and 
models between different programs and formats. The Systems Biology Markup Language (SBML) in 
particular is a machine-readable format for representing models of biological processes that has been 
evolving over the past several years [96]. SBML is becoming more widely adopted, both in the reporting 
and distribution of models, and in the import and export capabilities of software toolboxes. 
 
The application of advanced analytical techniques to the examination of high-throughput experimental 
data will continue to facilitate assembly of cancer models with increasing biological precision. However, 
several practical challenges, which impede the successful integration of data acquired from different 
experimental sources, or analyzed through different analytical methods, remain to be addressed. For 
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example, a recent report found that curated protein interaction datasets integrating multiple literature 
sources can be highly error-prone [100]. The fusion of data across multiple studies, performed at different 
times or by different laboratory groups, poses a substantial challenge for systems-level analyses that rely 
so strongly upon large and information-rich datasets. The Minimum Information for Biological and 
Biomedical Investigations (MIBBI) project is an example of ongoing efforts focused on developing and 
sharing “minimum information checklists” for experimental data. Such checklists place more stringent 
guidelines on the quality and content of published data [101]. Many journals and funding agencies already 
require authors reporting microarray data to comply with the Minimum information About a Microarray 
Experiment (MIAME) checklist [102]. Other minimal information guidelines which are gaining support 
in their respective communities include Minimum Information About a Proteomics Experiment (MIAPE) 
[103], Core Information for Metabolomics Reporting (CIMR), and Minimal Information About a RNAi 
Experiment (MIARE). The ability to estimate and compare the quality of different data integration 
schemes in the context of protein interactomics has also been the subject of recent investigation [104, 
105]. As these challenges continue to be addressed going forward, they promise the development of ever 
more powerful and biologically accurate in silico representations of human cancer. 
  
 
Statistically Derived Models of Cancer 
 
Statistical models of cancer can be broadly divided into those that employ unbiased statistical inference, 
and those that also incorporate a priori constraints of specific biological interactions from data (Figure 
2.3). Statistical models of cancer biology at the genetic, chromosomal, transcriptomic, and pathway levels 
provide insight about molecular etiology and consequences of malignant transformation despite 
incomplete knowledge of underlying biological interactions. These methods can help to elucidate key 
biomolecular events and pathways in oncogenic processes. They thus represent an important paradigm for 
both the fundamental characterization of cancer systems and the discovery of molecular targets for 
diagnostic or therapeutic applications. Several studies have sought to infer the structure of small and 
large-scale biomolecular networks in human cells. These methods can describe previously known 
biological pathways and can also be used to generate novel hypotheses about potential unknown 
interactions, which can then be studied more thoroughly through experiments. However, multiple 
experimental and analytical challenges still remain in the statistical study of cellular and physiologic 
cancer systems, which must be overcome to yield increasingly useful insights into cancer biology. 
 
Gene Expression Models for Cancer Diagnosis, Stratification, and Prognosis 
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The discrete mutational events found in the cancer genome and epigenome substantially modulate 
transcriptional profiles within cancer cells. Models based on these perturbed gene expression signatures 
can be applied for the diagnosis of disease subtypes as well as for stratification of tumor grade or 
prediction of therapeutic response (Figure 2.1). These models apply deterministic or probabilistic rules to 
model the molecular context through which a cell or tissue progresses to malignancy. Different 
transcriptional classifiers have been developed for the discrimination of cancer type, subtype, and grade 
[106-108], including hierarchical clustering [109, 110], k-means clustering [111], support vector 
machines [112], artificial neural networks [113, 114], and classifiers based on the relative expression of 
gene pairs [115-118]. Transcriptomic signatures, which represent oncogenic processes as a function of 
gene expression levels, have also been applied to model relapse and overall survival in diverse cancers, 
including non-small-cell lung cancer and pediatric leukemia [119-122]. Additionally, transcriptional 
classifiers have been used to predict tumor response to chemotherapeutic agents [123-125], which 
represents one of the most important clinical determinations in oncology practice. 
 
These models often begin with genome-scale microarray data and, through either computational or 
combined computational and experimental analyses, derive prognostic classifiers comprised of a smaller 
number of highly relevant transcripts. The statistical analysis of molecular signatures has potential utility 
for informing small molecule, radiological, and surgical cancer treatment choices that cannot be filled by 
standard histopathological or clinical analyses. While these transcriptomic models have not entered 
widespread clinical use, they embody a promising direct application of cancer models to medicine. 
Furthermore, such models may be more widely adopted as nucleotide measurement technology itself 
becomes more common in non-research contexts. Transcriptional models of cancer also provide an 
accessible characterization of the molecular processes that mediate tumor initiation, progression, and 
sensitivity to medical interventions. 
 
Pathway Enrichment Models and Biological Discovery 
 
The genomics revolution has prompted substantial efforts towards comprehensively annotating biological 
functions of and associations among identified genes [78, 126]. Several curated databases have been 
established for grouping genes into modules of defined activity according to physical or functional 
association, such as Gene Ontology [81] and the KEGG database [127]. Multiple computational methods 
have been developed for the purpose of mapping genetic and transcriptional activity into these groups 
[128, 129]. These tools use diverse numerical methods to determine gene groupings whose activity, as 
represented by gene expression, is substantially modulated through malignant transformation. For 
example, Gene Set Enrichment Analysis [130] and related tools have been applied to identify pathway 
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perturbations in human cancers based on transcriptomic data, including tumors of the breast and prostate 
[131-133]. An alternative approach combines human protein-protein interaction network data with gene 
expression profiles for the classification of breast and lung cancer samples [7, 134]. These related studies 
have considered the cumulative activity of discrete pathways, as defined by protein interaction data, to 
discriminate between phenotypes. This approach yielded results of similar predictive accuracy to the more 
common individual gene-based classifiers discussed previously, and demonstrates the importance of 
integrating various data sources for biological modeling. Similar pathway-based analysis methods also 
have been applied as prognostic indicators of clinical tumor progression—and the most important 
pathways identified through these computational methods often overlap significantly with those known 
experimentally to be oncogenic [135-137]. 
 
These frameworks have been applied to diverse cancer systems and serve as a robust source of biological 
discovery at the genome scale. That said, mapping genetic activity into discrete, human-defined gene sets 
clearly does not accurately recapitulate the full biological complexity encoded by historical evolutionary 
constraints. Rather, it is a useful tool that leads to further, more detailed studies. Indeed, a large portion of 
fundamental eukaryotic cell biology remains poorly characterized. This includes complex events such as 
non-coding transcription and epigenetic phenomena, but also more basic information such as the specific 
components and mechanisms of various signaling cascades. As such, pathway annotations themselves are 
subject to incomplete information and biases in curation. Nonetheless, these techniques, while coarse-
grained, enable the simultaneous consideration of many cellular pathways and processes using high 
throughput data. 
 
 
Network-Based Statistical Inference 
 
In silico cancer models based on statistical analysis of genetic aberrations, transcriptional activity, and 
pathway enrichment can provide important insights into the molecular phenomena that generate and 
propagate malignant cells. However, to characterize specific biomolecular mechanisms that drive 
oncogenesis, genetic and transcriptional activity must be considered in the context of cellular networks 
that ultimately drive cellular behavior [138-141]. In microbial cells, network inference tools have been 
developed and applied for the modeling of diverse biochemical, signaling, and gene expression networks 
[142-145]. Due to the much larger size of the human genome compared to microbes, and the substantially 
increased complexity of eukaryotic genetic regulation, inference of transcriptional regulatory networks in 
cancer presents increased practical and theoretical challenges. Additional complexity arises from the 
various data sources needed for studying human systems such as immortalized cell lines, primary cell 
lines, animal models, and tissue biopsies, which each provide imperfect recapitulation of in vivo cancer 
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biology and varying degrees of experimental malleability. Nonetheless, several efforts to infer cancer 
networks—at both the level of individual pathways and at the genome scale—have revealed important 
information regarding the molecular basis of oncogenesis. 
 
Network Inference at the Pathway Level 
 
This scale of challenge to construct quantitatively predictive network models at the genome scale in 
humans is not likely to be met in the near future [146], but more modest inference problems focusing on 
pathway-based subnetworks continue to prove useful. These studies examine different forms of biological 
data to infer causal relationships between genes at the transcriptional or signaling levels. For example, a 
multiparametric flow cytometry approach recapitulated a cell surface signaling pathway in the activation 
of human CD4+ leukocytes using a Bayesian network inference procedure [143]. Other studies have 
examined apoptotic signaling networks following experimental perturbation with pro-apoptotic TNF and 
other agents, using an innovative method in which downstream molecular perturbations are mapped into 
concordant “principal signaling components” [147, 148]. These studies have shown that a small number 
of canonical signaling patterns can accurately describe even a complex cellular response such as 
apoptosis. Furthermore, by comparing signaling in different cell types with differing phenotypic 
responses, it was found that differential upstream signaling—at the level of kinase activation, for 
example—most strongly mediates cell-specific stimulus response, but that different signals are 
propagated through common intracellular networks. 
 
 A recent examination of receptor tyrosine kinases found that the complex and overlapping cross-talk 
involved in such signal transduction can be explained substantially by linear combinations for docking 
affinities for downstream proteins [149]. This study represents a systems-level characterization of an 
important cellular system that is too complex to be fully explicable using traditional “univariate” 
biological modeling. Another recent study considered the cross-talk between phosphorylation pathways to 
predict the effects of inhibitor treatment on cancer cell migration phenotype [150]. This study 
characterized off-target and cross-talk effects of kinase inhibitor treatment to predict the effects of 
combinatoric treatments to forestall cell migration—an important malignant phenotype in cancer. Using 
different experimental and computational tools, these pathway-centric inference procedures have revealed 
important insights into diverse systems-level events in cancer that can have significant applications to 
pharmaceutical development and target selection. 
 
These network inference studies incorporate a priori information in the design of the experiment itself—
for example, in guiding the selection of what to measure (genes, proteins, and/or phosphorylation events) 
and the planning of perturbation experiments to informatively test the system. This model-guided 
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approach constitutes a reduction and focusing of network search space that increases the fidelity of 
network inference. These methods are not easily extendable to the inference of larger and more complex 
networks, as the larger number of variables introduces a much larger amount of possible interactions, with 
associated experimental noise and statistical uncertainty. As larger networks are examined, the task of 
“model identifiability” becomes an increasingly refractory but critically important challenge. 
 
Network Inference at the Genome Scale 
 
The inference of biological networks at the genome scale involves several challenges for eukaryotic 
systems, and thus most network inference methods have been developed initially using unicellular 
organisms. One example is the “Inferelator” computational suite, which has been used to infer a genome-
scale transcription regulatory network in the unicellular archaeon Halobacterium [151, 152]. This study 
constructed a network model of transcription able to determine the level of expression of each gene given 
the expression state of transcriptional regulators. The model was able to predict quantitatively the 
response of the organism to novel stimuli that were not used to train the model itself. This type of 
quantitative inferred genome-scale transcriptional regulatory network in humans remains a difficult and 
ongoing challenge.  
 
Nonetheless, efforts have been made to craft network-based statistical models of human cells, including in 
breast cancer and lymphoma, in which the architecture of regulatory networks for a portion of the human 
genome is characterized [153-156]. These models have applied Bayesian network inference methods 
[157] to discriminate physical or functional interactions between several thousand genes. The related 
probabilistic Boolean network formalism [158] has been used to construct regulatory networks in the 
context of several cancer systems, including glioma [159]. One study of melanoma adapted Boolean 
network analysis to include the use of “seed” genes, in which groups of genes believed to interact were 
used as a subnetwork starting point which was then iteratively grown to incorporate other related genes 
[160]. Many network inference methods appear robust when validated on synthetic data, but exhibit 
substantially reduced performance when applied to experimental gene expression datasets [161-163]. 
These results speak to the substantial complexity of gene regulation networks—even in the context of 
unicellular organisms—and to the requirement for large datasets in network inference tasks [164]. 
 
Statistically inferred network models can be used to study the topology of complex cellular systems, and 
elucidate important genetic interactions and control points. Such statistical networks map the status of 
regulatory agents into qualitative interactions with cognate targets and discrete network states. Going 
forward, the acquisition of larger high-throughput datasets encoding different facets of regulatory 
interactions, combined with innovative methods for their integration and analysis, will enable the 
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construction of increasingly precise numerical network models. The important ability to reliably model 
the behavior of cancer cells, for example upon response to treatment or genetic evolution, would hold 
significant implications for the development and administration of cancer treatments. 
 
 
Biochemical Reaction Networks 
 
In contrast to statistically inferred networks, biochemical reaction networks are constructed to represent 
explicitly the mechanistic relationships between genes, proteins, and the chemical interconversion of 
metabolites within a biological system (Figure 2.2). In these models, network links are based on pre-
established biomolecular interactions rather than statistical associations; significant experimental 
characterization is thus needed to reconstruct biochemical reaction networks in human cells. These 
biochemical reaction networks require, at a minimum, knowledge of the stoichiometry of the participating 
reactions. Additional information such as thermodynamics, enzyme capacity constraints, time-series 
concentration profiles, and kinetic rate constants can be incorporated to compose more detailed dynamic 
models.  
 
Stoichiometric Models of Biochemical Reaction Networks 
 
The most basic mathematical representation of a biochemical reaction network is a stoichiometric model. 
Stoichiometric models describe the interconversion of biomolecules purely in terms of the number of 
reactants and products participating in each reaction. The generation of stoichiometric models and 
analysis of their properties is a well-established process [50-52], and genome-scale models of metabolism 
have been completed for a diverse range of organisms, including the prokaryote E. coli [53], archaea [54], 
and eukaryotes such as S. cerevisiae [55] and the protozoan L. major [56]. Most important for cancer 
research is the recent reconstruction of known human metabolism at the genome-scale [165, 166]. 
Methods have also been developed for reconstructing signaling networks [167-169], transcriptional and 
translational networks [50], and regulatory networks [170, 171]; these models are fundamentally 
analogous to reconstructed metabolic networks (Figure 2.3). The reconstruction of a biochemical reaction 
network results in a database of stoichiometric equations that can be represented mathematically to form 
the foundation of a genome-scale, computable model. Computational tools for constraint-based analysis 
are then used to interrogate the properties of the reconstructed network in silico, and to facilitate model-
driven validation and refinement [57]. Physico-chemical and environmental constraints under which the 
network operates are applied in the form of balances, including mass, energy, and charge, and bounds, 
such as flux capacities and thermodynamic constraints. The statement of constraints defines a solution 
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space comprising all non-excluded network states, thereby describing possible functions or allowable 
phenotypes. These methods are now being adapted for modeling human systems in greater detail. 
 
Constraint-based analysis of biochemical reaction networks has been applied to a number of human 
systems. Using the reconstruction of the human mitochondrial metabolic network [172], linear 
programming and random sampling were applied to identify candidate steady states of the network under 
normal, diabetic, ischemic, and dietetic conditions [173]. In a related study, Monte Carlo sampling of flux 
spaces was used to study the effects of enzymopathies on the human erythrocyte metabolic network [174]. 
A stoichiometric formalism was also used to reconstruct reactions comprising the JAK-STAT signaling 
network in the human B-cell [175]. In this study, a topological constraint-based approach was employed 
to evaluate network cross-talk, redundancy in signaling inputs and outputs, and to delineate correlated 
reaction sets or systemic modules. The recent completion of a global reconstruction of the human 
metabolic network [165] represents a significant milestone in human systems biology—and clears a path 
forward for reconstructing metabolic models for all of the 200 cell types in the human body and their 
modified forms in various cancers. This reconstruction comprises 1,496 genes and 3,748 reactions divided 
into 88 metabolic pathways. In addition to the typical network capabilities determined by constraint-based 
modeling, the initial genome-scale reconstruction has enabled analysis of relationships between network 
topology and human metabolic diseases [176]. An independently reconstructed human metabolic network 
[166]—comprising 2322 and 2823 reactions among 70 different pathways—was also used to demonstrate 
the potential of systems modeling in human metabolism to aid in drug discovery [177]. An important 
effort going forward will be to resolve the discrepancies between different versions of the human 
reconstructions, establishing a consensus global reconstruction of human metabolism. 
 
Modeling Metabolism in Human Cancer 
 
The global human metabolic reconstruction provides a basis for the known set of metabolic reactions 
catalyzed by human proteins. However, the utility of these models for cancer research going forward 
depends upon overcoming several challenges. First, further refinement of the global human metabolic 
map is essential to increase its accuracy. Second, each of the approximately 200 cell types in the human 
body exhibits only a portion of the full metabolic capability contained in the genome [178] (Table 2.2). 
The high percentage of undetermined activities for metabolic enzymes in human tissues clearly shows 
how much more we have to learn about even this very well studied cellular process. Effectively 
representing which portions of the global human metabolic network are active in any given cell type, and 
at what level, is thus of critical importance. Cancers in particular are known to exhibit diverse metabolic 
phenotypes compared to their progenitor cells, typically with an increased rate of overall metabolic 
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activity to support their increased growth and the highest metabolic activity observed in the most 
aggressive malignancies [179, 180]. Multiple other hallmarks of cancer including angiogenesis, 
metastasis, evasion of apoptosis, and avoidance of immune detection have been previously linked to 
human tumor metabolism [41, 43]. Metabolic targets have also been used in cancer chemotherapy [181-
183]. For these reasons, metabolic networks in human cancer have the potential to be a rich focus area for 
systems modeling going forward. 
 
Kinetic Models of Biochemical Reaction Networks 
 
Detailed dynamic models are needed to accurately quantify many important molecular processes, such as 
feedback and feedforward regulation, competitive inhibition, post-translational modification, and 
transcriptional regulation. At scales much smaller than the genome, biochemical reaction networks have 
been used as the basis for forming dynamic differential equation models with the addition of kinetic rate 
constants [167, 184, 185]. Many of the fundamental considerations and challenges associated with 
constructing kinetic models of cell signaling pathways have been previously reviewed in detail [186, 
187]. Briefly, these models are most commonly formulated as a set of ordinary differential equations 
(ODEs). In these ODE-based pathway models, the rates of production and consumption of individual 
biomolecular species is described in terms of mass action kinetics (elementary reactions with forward and 
reverse rate constants). As the full kinetic detail for reactions in biological pathways is often unknown, 
simplifying assumptions such as the Michaelis-Menten approximation or time-scale separation can be 
applied. Kinetic models are advantageous in that they do not employ a steady-state assumption as 
constraint-based models typically do, and thus can simulate detailed dynamic behavior. Dynamic models 
are also able to simultaneously account for both the concentrations of compounds and flux through 
reactions. Capturing dynamics however, requires more parameters, and thus these models are more data 
intensive to create as well as more prone to overfitting when parameters must be estimated. Nevertheless, 
smaller scale dynamic models have been used successfully to study in mechanistic detail key pathways 
related to human cancer. Most of the pathways and molecular components listed below do not function 
independently to promote oncogenesis, but rather are often connected through signaling cross-talk, 
feedback mechanisms, and other forms of up- or downstream regulation. These examples are not an 
exhaustive list, but serve to demonstrate the benefits of detailed kinetic modeling of biological pathways. 
 
Aberrant activity of the transcription factor NF-κB has been linked to oncogenesis, tumor progression, 
and resistance to chemotherapy. A computational ODE model was employed to determine the role of 
inhibitor of NF-κB kinase (IκB) isoforms in the temporal control of NF-κB [167]. Analysis of the model 
revealed that IκBα is responsible for strong negative feedback and fast turn-off of the NF-κB response to 
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IKK stimulation, while IκBβ and IκBϵ reduce oscillations in the signaling module and stabilize NF-κB 
response during longer stimulation. The same model was expanded and used to study dynamics of IκB–
NF-κB signaling module when cells were stimulated by lipopolysaccharide (LPS) via Toll-like receptor 4 
(TLR4) [184, 188]. Modeling of two TLR4-dependent signaling pathways suggested that one pathway 
required the expression tumor necrosis factor-α (TNFα) to activate NF-κB. 
 
In another study, the negative feedback loop between the tumor suppressor p53 and the Mdm2 oncogene 
was examined experimentally and computationally [189]. Different mathematical models of the system 
were analyzed to draw connections between predicted and experimentally observed behavior. The models 
indicated that low-frequency noise in protein production rates was an important source of variability in 
oscillations of the p53-Mdm2 system. Another model was built for the single-cell response of p53 to 
radiation-induced DNA damage [190]. In agreement with experiments, simulations showed that by 
assuming stochasticity in the initial number of double-strand break sites and the DNA repair process, p53 
and Mdm2 exhibit coordinated oscillatory dynamics with radiation stimulation.  
 
Numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by 
malignant perturbations such as amplification, mutation, and translocation in cancer patients. Activation 
of the PI3K pathway results in aberrant cell growth and survival, metastatic competence, and therapy 
resistance. An excellent review of the challenges, opportunities, and progress in modeling and exploiting 
the PI3K pathway can be found in Hennessy et al., 2005 [191]. For example, inhibitors of the mTOR 
pathway have been demonstrated to directly target PI3K signaling. However, due to the intricate role of 
mTOR in regulation of PI3K/AKT signaling, detailed understanding of the pathway derived from 
computational modeling is needed to determine the consequences of inhibition of particular components.  
 
A number of models have been used to examine mechanisms that govern mitogen-activated protein 
kinase (MAPK) pathway dynamics. MAPK pathways are involved in the activation of many cancer-
promoting genes and respond to a number of different cancer-associated stimuli, such as epidermal 
growth factor (EGF). A computational model of general MAPK signaling pathways was used to study the 
role of negative feedback mechanisms in generating complete signal adaptation (i.e., desensitization to 
stimulus) [192]. Another model was used to simulate EGF-induced MAPK activation [193]. Analysis of 
model simulations provided quantitative evidence that feedback inhibition of the MAPK cascade is the 
most important factor in determining the duration of cascade activation. It was also found that differences 
in EGF and NGF-stimulated signaling could be accounted for by differential feedback regulation of the 
MAPK cascade. Similarly, a model was constructed to examine the signal-response relationships between 
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EGF binding and the activation of downstream proteins in the cascade [194]. Model predictions showed 
that EGF-induced responses are remarkably stable over a 100-fold range of ligand concentration. 
 
Another model used dynamic simulations of gene expression and signaling networks to study behavior in 
human cancer cells [195]. While dynamic interaction networks of cancer systems are challenging to 
construct and simulate, such models are essential to capture the molecular complexity of oncogenesis. 
Taken together, these studies provide powerful examples of how building a model that correctly explains 
data and makes verifiable predictions can lead to deepened insight into biological mechanism and 
function. 
 
 
Microenvironment and Tissue-Level Models 
 
In silico models of cancer can be built not only for intracellular networks, but also at larger length scales. 
Alternative computational methods must be applied to consider the interface between cancers and the 
tissue contexts in which they reside. These settings exhibit complex interactions with multiple factors of 
different function and scale, including extracellular biomolecules, a spatially intricate and dynamic 
vasculature, and the immune system [196]. Models of cancer at the tissue level that account for these 
functionally divergent parameters can be broadly divided into “continuum” models and discrete or 
“agent-based” models [197-199]. The latter are often applied when the number of individual interacting 
units, such as cancer cells, is constrained to remain small; the former is more practical at population 
scales where agent-based modeling can be computationally prohibitive. Both methods can integrate 
information about the biological context in which cancers develop, and thus represent a multi-scale 
consideration of oncogenesis as it occurs within somatic tissues [200]. 
 
Continuum Models 
 
Extracellular parameters can be represented as continuously distributed variables to mathematically 
model cell-cell or cell-environment interactions in the context of cancers and the tumor 
microenvironment. Systems of partial differential equations have been used to simulate the magnitude of 
interaction between these factors, including the effects of hypoxia on cell cycle progression [201], the 
impact of mechanical forces on tumor invasiveness [202], and extracellular matrix interactions [203]. 
Recent studies have examined cell population dynamics within colonic crypts in colorectal cancer [204, 
205]. These models consider interactions between stem cells, differentiating cells, and differentiated cell 
populations to quantitatively predict tissue-level invasion and the growth of tumor mass. Other models 
have represented solid tumors as a multi-phase system of both bound and “mobile” forms [206, 207]. 
Such “mixture” models consider differential growth and apoptosis rates as well as mass transfer and 
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regulatory interactions between phases. Alternative models have considered nonlinear and combinatoric 
effects of multiple factors, including nutrient availability and mechanical parameters [208, 209] and the 
effects of mutation rate on invasion and metastasis [210]. These numerical systems embody a robust 
method to incorporate the effects of somatic biological phenomena into computational representations of 
cancer. Continuum-based models are thus powerful tools to simulate and characterize interactions 
between intracellular and extracellular factors in oncogenic processes. 
 
Cellular Automata and Agent-Based Models 
 
Multivariate continuum models are able to represent the effects of several physiological or biochemical 
events on cancer development. However, in situ, these factors are highly heterogeneous, and interact 
discontinuously with tumor cells [211, 212]. Cellular automata models represent cancer cells as discrete 
entities of defined location and scale, interacting with one another and external factors in discrete time 
intervals according to predefined rules [213]. Agent-based models expand the cellular automata paradigm 
to include entities of divergent functionalities interacting together in a single spatial representation, 
including different cell types, genetic elements, and environmental factors [214]. With sensitivity to 
starting conditions and the ability to incorporate probabilistic interactions at each time step, these models 
can exhibit similar stochastic behaviors to those observed in oncogenesis in vivo [215-217]. Phenomena 
that have been modeled using agent-based models include three-dimensional tumor cell patterning [218], 
immune system surveillance [219], angiogenesis [220-222], and the kinetics of cell motility [223]. 
Another recent model integrated diverse parameters such as extracellular signals, blood flow, and tissue 
degradation to simulate the spatiotemporal formation of tumor vasculature [224]. 
 
Increasingly, “hybrid” models have been created which incorporate both continuum and agent-based 
variables in a modular approach. For example, a recent study considered continuous extracellular 
biomolecule distributions and discrete cell locations to simulate the interaction between intracellular 
decision-making processes and malignant growth [225]. Another recent model incorporated a continuous 
model of a receptor signaling pathway, an intracellular transcriptional regulatory network, cell-cycle 
kinetics, and three-dimensional cell migration in an integrated, agent-based simulation of solid brain 
tumor development [226]. The interaction between cellular and microenvironment states have also been 
considered in a multiscale model that predicts tumor morphology and phenotypic evolution in response to 
such extracellular pressures [227]. These and other techniques that incorporate multiple, nested scales of 
interacting biology embody promising paradigms to understand cancer as a cascade of information across 
levels of size and complexity. The ability to interrogate cancer across multiple biological agents and 
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compartments presents a unique framework to elucidate oncogenic processes and to evaluate potential 
therapeutic interventions through digital simulation prior to experimental deployment. 
 
 
Conclusions & Future Directions 
 
The ability to model the initiation and progression of human cancer at the level of molecules, cells, and 
tissues is important to improve cancer diagnosis and treatment. In Chapter 1, I have discussed the 
biological motivations for in silico models of cancer with regards to the molecular complexity observed in 
the disease, which is best understood in the context of systems-level interactions. Similarly, tumors 
interface with an intricate environment of several cell types and extracellular factors, an additional layer 
of complexity that will require systems-based approaches to address reliably. Powerful new technologies 
enable the high-throughput biological measurements critical to understanding these processes, including 
nucleotide sequencing, proteomics, and protein interaction assays. Additionally, the standardization and 
distribution of this data through common file formats and internet databases empowers the research 
community to build efficiently upon previous studies and to cumulatively expand our knowledge of the 
disease. Predictive models serve as compact and rigorous representations of large-scale hypotheses for the 
functioning of disease-perturbed networks and promise to advance rational therapy design in the coming 
future of systems medicine.  
 
Diverse computational methods have been developed to analyze different elements of cancer biology, and 
to elucidate multicomponent, systems-level contributors to cancer development. Statistical models 
consider cancer cell biology at the pathway or genome scale to elucidate genetic or transcriptional 
signatures associated with oncogenesis. The ability to identify molecular signatures that can inform 
diagnosis and treatment selection is already beginning to take effect in the clinic, for example with 
molecularly targeted therapies such as imatinib (Gleevec) for selected subpopulations of cancer [228]. At 
a finer resolution, quantitative pathway-level models offer explicit representation of intracellular signaling 
and metabolic events in cancer, and important scientific successes have been observed with these 
mechanistic pathway models. Integration of many molecular pathways for quantitative genome-scale 
modeling remains an ongoing challenge, with statistical inference of cellular networks currently possible 
only in a very limited context in human cancers. At the physiological level, continuum and agent-based 
models efficiently describe the interaction between cancer cells and the surrounding tissue environment. 
Cumulatively, these models are able to integrate many different sources of experimental data to simulate 
and observe diverse aspects of cancer biology. Translation of these models to the clinic, while currently a 
slow process, suggests a substantial promise of systems medicine that is just beginning to be explored. 
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The future prospects for in silico models of cancer are substantial, and this field is clearly still in its 
infancy. With rapidly advancing technologies for biologic interrogation at the genetic, transcriptional, 
proteomic, and cellular levels, the body of data upon which models can be trained is expanding even 
faster. Coupled with the persistent exponential rise of computing power, the “raw materials” of systems 
biology will continue to improve at an exhilarating rate. With the broad availability of annotations for 
cellular pathways and biomolecular interactions, specific constraints can now be imposed across the 
genome on model architectures to enhance dimensional parsimony and statistical resolution. Additionally, 
a broad array of tools for numerical simulation of both individual biological modules and genome-scale 
phenomena has been developed. Going forward, the fusion of experimental, informational, and analytical 
modalities will provide a powerful analytical framework for in silico modeling of human cancer. 
 
In silico cancer modeling presents significant opportunities to investigate oncogenesis across biological 
scales and systems. These powerful methods should help to accelerate the development of diagnostic and 
therapeutic technologies for clinical medicine. Considerable improvement in the resolution, scale, and 
predictive power of these models must first be achieved, regarding which substantial challenges remain. 
Nonetheless, it may ultimately be possible to simulate oncogenesis and malignant invasion accurately 
from the scale of genetics to physiology. With this technology, distinguishing signatures of cancers could 
be discovered automatically for purposes of early diagnosis, prognosis, and treatment planning. 
Additionally, and perhaps most promisingly, with reliable digital representations of cancer, the effects of 
therapeutic interventions at both the molecular and surgical scales could be predicted in silico without 
exposing patients to risk. This innovation would greatly accelerate the development of safe and targeted 
anticancer therapeutics, and offer hope of medical treatments for diseases that remain refractory to current 
clinical technologies. Ultimately, while confronting substantial experimental and analytical challenges, in 
silico models of cancer are advancing, and promise to strongly enhance both the fundamental 
understanding of cancer and its treatment in the clinic. 
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Chapter 2 Figures & Tables 
 
 
 
Figure 2.1. Schematic overview of statistical modeling in human disease. 
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Figure 2.2. Comparison of biochemical reaction network and statistical network models. 
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Figure 2.3. Mathematical representation of reaction links in biochemical networks. 
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Table 2.1. Databases and software for building systems models of cancer. 
 
Resource Database Refs 
Genome sequence data Ensembl 
UCSC Genome Browser 
[78] 
[126] 
   
Genome annotation data   
Genetic elements Entrez Gene 
Gene Ontology Annotation (GOA) Database 
Universal Protein (UniProt) Knowledgebase 
Genome Reviews 
[229] 
[75, 77] 
[76] 
[79] 
   
Biochemical pathways &
functional associations 
Kyoto Encyclopedia of Genes and Genomes (KEGG) 
Gene Ontology (GO) 
The SEED 
MetaCyc 
BioCyc 
TransportDB 
[80, 127] 
[81] 
[84] 
[82] 
[83] 
[85] 
   
Regulatory Sequences Eukaryotic Promoter Database (EPD) 
Transcriptional Regulatory Element Database (TRED) 
[72] 
[73] 
   
Model, model parameter repositories Kinetic Data of Bio-molecular Interactions Database 
BioModels Database 
Database of Quantitative Cellular Signaling (DQQCS) 
[88] 
[86] 
[87] 
   
Protein interaction networks Database of Interacting Proteins (DIP) 
Molecular INTeraction Database (MINT) 
Mammalian Protein-protein Interaction Database (MIPS) 
[91] 
[92] 
[93] 
   
High-throughput genome-scale data   
Transcriptomics Gene Expression Omnibus (GEO) 
Standford Microarray Database (SMD) 
[70] 
[71] 
   
Proteomics Proteomics Identifications Database (PRIDE) [74] 
   
Visualization and data management software 
packages 
Cytoscape 
The Gaggle 
[99] 
[98] 
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Table 2.2. Predicted tissue-specific activity of metabolic genes in the human metabolic 
reconstruction (data from [178]). 
 
Tissue Active (of 1165) Inactive Undetermined 
Liver 12.4% 19.2% 68.4% 
Brain 7.0% 32.1% 60.9% 
Heart 4.2% 22.0% 73.8% 
Kidney 12.9% 21.5% 65.7% 
Lung 3.9% 33.6% 62.5% 
Pancreas 3.8% 35.5% 60.8% 
Prostate 2.8% 30.0% 67.1% 
Spleen 1.1% 38.5% 60.4% 
Thymus 1.0% 37.3% 61.6% 
Skeletal 
Muscle 4.6% 28.0% 67.4% 
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Chapter 3. Relative Expression Analysis for Molecular Cancer Diagnosis and Prognosis3 
 
The enormous amount of biomolecule measurement data generated from high-throughput technologies 
has brought an increased need for computational tools in biological analyses. Such tools can enhance our 
understanding of human health and genetic diseases, such as cancer, by accurately classifying phenotypes, 
detecting the presence of disease, discriminating among cancer sub-types, predicting clinical outcomes, 
and characterizing disease progression. In the case of gene expression microarray data, standard statistical 
learning methods have been used to identify classifiers that can accurately distinguish disease phenotypes. 
However, these mathematical prediction rules are often highly complex, and they lack the convenience 
and simplicity desired for extracting underlying biological meaning or transitioning into the clinic. In this 
chapter, I survey a powerful collection of computational methods for analyzing transcriptomic microarray 
data that address these limitations. Relative Expression Analysis (RXA) is based only on the relative 
orderings among the expressions of a small number of genes. Specifically, I provide a description of the 
first and simplest example of RXA, the k-TSP classifier, which is based on k pairs of genes; the case k = 1 
is the TSP classifier. Given their simplicity and ease of biological interpretation, as well as their 
invariance to data normalization and parameter fitting, these classifiers have been widely applied in 
aiding molecular diagnostics in a broad range of human cancers. I review several studies that demonstrate 
accurate classification of disease phenotypes (e.g., cancer vs. normal), cancer subclasses (e.g., AML vs. 
ALL, GIST vs. LMS), disease outcomes (e.g., metastasis, survival), and diverse human pathologies 
assayed through blood-borne leukocytes. The studies presented demonstrate that RXA—specifically the 
TSP and k-TSP classifiers—is a promising new class of computational methods for analyzing high-
throughput data, and has the potential to significantly contribute to molecular cancer diagnosis and 
prognosis. 
 
 
Expression Analysis for Molecular Signature Identification 
 
High-throughput measurements in biology (e.g., transcriptomics, proteomics, metabolomics) provide an 
enormous amount of information, but only implicitly, in the form of raw expression values. Harnessing 
this information means converting it to knowledge and, for the purposes of classification, useful decision 
rules. In particular, this conversion can enable a greater understanding of cancer and drive advances in 
personalized medicine. A systems-level approach, which employs computational and statistical tools to 
reveal and evaluate patterns with diagnostic or prognostic value, is critical to fully exploiting these new 
                                                     
3 This chapter includes material that was reproduced with permission from the following publication: Eddy, J.A., J. 
Sung, D. Geman, and N.D. Price. 2010. Relative expression analysis for molecular cancer diagnosis and prognosis. 
Technology in Cancer Research & Treatment. 9(2):149-159. (all sections; text was collaboratively written with 
Jaeyun Sung and Donald Geman). 
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technologies. In particular, molecular signatures derived from patterns in gene expression microarray 
experiments have great potential to detect the presence of disease, to discriminate among cancer sub-
types, to predict clinical outcomes, and to provide insight into specific changes that occur during disease 
progression.  
 
Perhaps the most evident challenge for developing useful molecular signatures is to identify classifiers 
that are accurate for a specific study or platform and that are also robust across a wide range of settings. 
Previous studies have aimed to identify sets of individual genes (“signatures”) whose differential 
expression is highly correlated with phenotypic changes (e.g., genes that may be over- or under-expressed 
in cancer relative to normal). In these cases, increased or decreased absolute mRNA concentration levels 
above some threshold (i.e., more than would be statistically expected by chance for a gene on the 
microarray) are put forth as candidates for disease-induced (or causing) perturbations. Unfortunately, the 
statistically significant genetic changes often depend largely on the context of the microarray experiment. 
Even when thresholds are tuned to produce statistically significant results, findings can depend heavily on 
a number of factors, such as the experimental design and the type of data normalization. Consequently, 
there may be little to no overlap in the molecular signatures identified from one platform to another, or by 
extension, from one clinical setting to another.  
 
A less evident, but equally important, challenge for phenotype classification using gene expression data is 
to develop techniques that not only yield accurate and robust decision rules, but also provide rules that are 
easy to interpret and might contribute to biological understanding. Advanced statistical learning and 
pattern recognition methods are routinely applied to transcriptomics and other high-throughput data types. 
These include neural networks [230-232], decision trees [233-235], boosting [234, 236], and support 
vector machines [237, 238]. In many cases, these methods achieve good classification performance, with 
sensitivities and specificities above ninety percent. However, they generally result in extremely complex 
decision rules based on nonlinear functions of many gene expression values. Therefore, whereas 
advanced methods may be more accurate than those based on the patterns of individual genes, they 
usually produce decision rules that are virtually impossible to interpret. Furthermore, as the number of 
variables (transcripts) far exceeds the number of observations in most microarray studies, building more 
complex classifiers entails a greater risk of over-fitting the training data and poor generalization. 
 
An important potential benefit of simple and interpretable decision rules is to provide insight into the 
underlying biological differences between phenotypes. Notably, malignant phenotypes in cancer arise 
from the net effect of interactions among multiple genes and other molecular agents within biological 
networks. Genes in networks operate in a combinatorial manner—the actions of one gene greatly 
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influence the actions of other genes. This often limits the information that can be gleaned from the 
expression patterns of individual genes. As an alternative approach, studying gene expression in the 
context of networks may yield greater insight into mechanisms and functional changes associated with 
disease. Recently, methods for analyzing microarray data have focused not on individual genes, but 
instead on biologically meaningful pathways or networks [128, 239-241]. These frameworks have been 
applied to diverse cancer systems and serve as a robust source of biological discovery [240, 242]. 
 
At scales smaller than biological networks or even pathways, assessing the relationships among a small 
number of genes—for example, the patterns of interactions among just two or three genes—can provide 
useful information about biomolecular processes. One way to probe the interactions among several genes 
is to study their relative expression, i.e., the ordering among the expression values, rather than their 
absolute expression values. One then searches for characteristic perturbations in this ordering from one 
phenotype to another. The simplest form of such an interaction is the ordering of expression among two 
genes, in which case one seeks to identify typical “reversals”—pairs of genes for which one of the two 
possible orderings is usually present in one phenotype and rarely present in the other. We refer to the 
family of such rank-based methods as Relative Expression Analysis (RXA). This methodology is 
characterized by replacing each expression level across all genes by its corresponding rank within a single 
microarray profile.  
 
Here, I focus on RXA methods that involve a small number of gene pairs, each exhibiting a characteristic 
“relative expression reversal” between the phenotypes or classes of interest. Aggregating the decisions 
from a few such pairs, even just one, is surprisingly powerful. Basing decisions on one pair is called the 
top-scoring pair (TSP) classifier [243] and on k pairs is called the k-TSP classifier [116]. Thus, in TSP, a 
sample is classified based on a decision rule that only involves comparing the ranks, hence the relative 
expression levels, of two genes within a profile. For the k-TSP classifier, the decision rule combines a 
disjoint set of TSPs by simple majority voting. Other RXA methods include those based on the six 
possible orderings among three genes (the top-scoring triplet classifier [244]) and comparing the average 
ranks in two groups of genes [117]. Herein I review the TSP and k-TSP computational methods, focusing 
on their utility for aiding molecular diagnostics in a broad range of human cancers. This review is largely 
restricted to applications with transcriptomic data, as this is the most plentiful and has been the most used 
to date. However, RXA is generally applicable to any ordinal data type, such as protein expression, DNA 
copy number, chromosomal position, and so forth. 
 
 
Relative Expression Analysis 
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Microarray Data and Analysis 
 
For those readers less familiar with computational approaches to microarray analysis, I first describe the 
typical features of microarray data and common procedures relevant to the results presented here. 
Whereas I discuss computational analysis of microarray data in the context of RXA (Figure 3.1), the 
notation, representation of the data, and basic steps are similar for other approaches. Computational 
analysis of microarray data typically involves two steps. First, a classifier is trained on a collection of 
microarray profiles (samples) referred to as the training set. This involves selecting a subset of genes and 
choosing a mathematical algorithm (decision rule) to apply to the selected genes in order to determine the 
phenotype of a new sample. Of course the goal is to identify an algorithm that is predicted to work well 
on a new dataset, and the second step is then to evaluate the performance of the classifier on held-out 
data. Usually, the algorithm works quite well on the training data, and hence validation is essential.  
 
Microarray data are typically represented as a matrix of G rows of genes and N columns of samples (e.g., 
different tumors, tissues, patients, time points). The nth column of this matrix is therefore a G x 1 vector 
representing the expression profile xn of the nth sample. Each profile contains expression values for gene 
one (g1) through gene G (gG). The expression level of the gene gi is denoted by Xi. In addition, each 
sample is labeled by a phenotype Y ∈ {A, B, …}. For example, yn = A indicates that the nth sample 
belongs to phenotype A. The labeled dataset to be used for classifier training is F = {(x1, y1), …, (xN, 
yN)}. 
 
As mentioned above, the simplest method for classifying expression profiles based on the relative 
ordering of expression values is the top-scoring pair (TSP) algorithm for distinguishing between two 
phenotypes A and B. In TSP, a particular pair of genes i and j is selected during training and the decision 
rule is simple maximum likelihood: for the sample to be classified, choose the class, A or B, for which the 
observed ordering between the expression values of gi and gj is the most likely. Notice that the observed 
ordering is either Xi < Xj or Xi > Xj (we can assume at this point that ties are broken at random). The pair 
which is chosen is the one that achieves the highest "score" among all pairs of genes. This score is a 
quantitative measure of the degree of relative expression reversal estimated from the data and used for 
classifier training, as explained in the following section. For the k-TSP classifier, the decision rules are 
conceived in the same manner as in the TSP classifier, but use a combination of gene-pair markers to 
obtain potentially better classification accuracy. There are currently three software implementations 
available for researchers who wish to apply these methods: one in Perl [116], one in R [245], and one, 
developed by myself and fellow graduate student John Earls, that provides a graphical user interface 
wrapped around Python functions [246].  
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The TSP and k-TSP classifiers are parameter-free methods that are invariant to all normalization 
techniques that are monotonic transformations of the original expression values within each chip or 
microarray. That is, if the data are processed in such a way that if gene gi is expressed more than gene gj 
before normalization (original data) and it is still expressed more after normalization (processed data), 
then the TSP and k-TSP classifiers derived from the original and processed data are the same. It is in this 
sense that these classifiers are “invariant” to normalization. Moreover, the TSP and k-TSP classifiers are 
especially favorable in terms of the simplicity of the decision rule and the small number of genes involved 
in classification. They are easy to implement in practice, as the classifier only requires measurement of 
the expression of small numbers (at most 2k) of genes using techniques such as RT-PCR. They also 
remain context-independent by not requiring any parameter tuning or data pre-processing based on genes 
outside of the pairs involved. Furthermore, because data normalization is not required, RXA classifiers 
have been shown to be useful in the integration of data across different studies and platforms for the 
purpose of increasing sample size and facilitating meta-analysis of microarray data [247].  
 
Training RXA Classifiers 
 
In relative expression approaches, the features selected are pairs of genes. Consider first TSP. Because 
only gene pairs are considered, it is possible to completely enumerate all possible pairs and select the 
“best” ones using the training data. The natural criterion is performance, which anticipates how the pair of 
genes will be used for classification. As a result, one then selects the pair of genes gi and gj for which the 
difference |Prob(Xi < Xj | Y = A) – Prob(Xi < Xj | Y = B)| is maximized. This can be shown to be equivalent 
to choosing the pair of genes that achieves the lowest error rate on the training set. In many cases, there is 
a single pair of genes achieving the top score. Otherwise, in order to select a unique pair of genes, a 
secondary score is applied, which is based on the average difference in expression values over all 
samples. An important feature of the top-scoring pair of genes is that it may not be the case that both 
genes are highly differentially expressed on the basis of their individual t-statistics; in fact, one gene may 
serve as a “pivot” for the other.  
 
Depending on which of the two probabilities Prob(Xi < Xj | Y = A) or Prob(Xi < Xj | Y = B) is larger, the 
decision rule is either: 
 
   Rule 1: If expression gene i < expression gene j, THEN class A, ELSE class B. 
   Rule 2: If expression gene j < expression gene i, THEN class A, ELSE class B. 
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In the case of k-TSP, the classifier is constructed from the k top-scoring pairs of genes. Each pair votes for 
class A or class B the same way as in TSP, and the class with the majority vote is chosen. Effectively, this 
is the maximum likelihood rule: choose the class for which the k observed orderings are the most likely. 
Usually, the pairs are constrained to be “disjoint,” meaning that a gene cannot appear in more than one 
pair, and the number of pairs (k) is determined by cross-validation up to some limit (e.g., kmax = 10) in 
order to keep the total number of genes manageable. Consequently, the size of the gene “signature” is two 
for TSP and 2k for k-TSP. Unlike other methods, once the signature is determined so is the classifier. That 
is, there are no parameters to tune, which reduces over-fitting the training data.  
 
Testing RXA Classifiers 
 
Classifier training is followed by performance evaluation on a test dataset. The gold standard for testing 
any predictive method is to use an independent dataset collected solely for testing. However, due to the 
scarcity of data, the test set usually consists of samples selected from the original training dataset and set 
aside. Even in this case, repeated training and testing, known as cross validation, is preferred due to small 
sample sizes. Such procedures involve splitting the original training dataset F into two smaller sets: the 
set of samples on which the classifier is trained, Ftrain; and the set of samples on which the classifier is 
tested, Ftest. Importantly, no information from Ftest can be utilized when learning the classifier on Ftrain. 
The data is repeatedly split into training and test groups, and the cross-validated accuracy is the average 
classifier performance across all test groups. Leave-one-out cross validation (LOOCV) is commonly used, 
in which the total of N samples is divided into a training set of size N – 1 with the test set consisting of the 
single remaining sample. While error estimation with LOOCV is known to have high variance relative to 
the true error [248], it is particularly useful for TSP and k-TSP because there is a technique [116] that 
yields a very significant reduction in the computation involved in looping over all pairs of genes in each 
loop of cross validation. 
 
A number of different metrics can be used to measure the performance of classifiers. Particularly common 
measures include sensitivity, specificity, and overall accuracy. These metrics are most easily understood 
for experiments with a case (e.g., cancer) and a control (e.g., normal), but can be extended to any binary 
phenotype comparison as well as extended to multiclass problems by decomposing them into sets of 
binary comparisons. If a classifier correctly predicts that a cancer profile belongs to the cancer class, this 
is known as a true positive (TP), and the probability of correctly labeling future cancer samples is the 
sensitivity of the classifier (also known as the true positive fraction). Similarly, a true negative (TN) is 
when a classifier correctly labels a normal sample, and the probability of doing this on new samples is the 
specificity of the classifier. Importantly, the sensitivity and specificity computed on the samples used for 
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training are upwardly biased and not predictive of cross-validated rates. Finally, overall accuracy can be 
defined in several ways; perhaps the simplest is the average of sensitivity and specificity.  
 
 
RXA in the Study of Cancer  
 
Cancer Studies Using Relative Expression Values Before TSP and k-TSP 
 
Gene-pair relative expression markers, specifically in the form of a two-gene expression-level ratio, have 
been previously used for disease classification and prognosis. Gordon et al. [249] successfully 
distinguished between malignant pleural mesothelioma (MPM) and adenocarcinoma (ADCA) of the lung 
based on ratios of expression. Although genetically disparate, the tissues of MPM and ADCA can be 
difficult to distinguish based on established histopathological methods. Gorden et al. [249] tested the 
fidelity of ratio-based diagnosis in differentiating between the two tissue types in 181 samples (31 MPM 
and 150 ADCA). First, the investigators used a training set of 32 samples (16 MPM and 16 ADCA) to 
identify differentially expressed genes based on various methods (fold changes, standard t-tests, 
expression cutoffs, etc.). They then formed 15 ratios using individual or combinations of those genes that 
showed the highest significance in inversely correlated expression levels. Any single ratio of the 15 
examined was at least 90% accurate in predicting diagnosis for the remaining 149 samples (e.g., test set). 
They then examined (in the test set) the accuracy of multiple ratios combined to form a simple diagnostic 
tool. Using two and three expression ratios, the investigators found that the differential diagnoses of 
MPM and lung ADCA were 95% and 99% accurate, respectively. Whereas, in this study, these gene-pairs 
are not combined in the same way as TSP, they are sensitive to normalization and parameter choices. 
Still, their work illustrates the utility and discriminatory power of gene pairs in important clinical 
diagnoses. 
 
Ma et al. [250] found that a two-gene expression ratio derived from a genome-wide, oligonucleotide 
microarray analysis of estrogen receptor (ER)-positive, invasive breast cancers predicts tumor relapse and 
survival in patients treated with tamoxifen. Tamoxifen is one of the most commonly used medications in 
the treatment of early-stage and metastatic ER-positive breast cancer [251, 252]. When administered to 
women with surgically treated ER-positive breast cancer, tamoxifen therapy reduces the annual risk of 
recurrence by 40-50%, leading to a 5.6-10.9% improvement in 10-year survival [253]. However, 25-66% 
of women diagnosed with ER-positive breast tumors fail to show a prolonged response or develop early 
resistance to adjuvant therapy [251, 254]. Currently, there are no markers that reliably predict clinical 
outcome of cancer patients treated with tamoxifen. Therefore, a reliable means to accurately predict 
tamoxifen treatment outcome is crucial for early-stage breast cancer management. 
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In the tamoxifen study conducted by Ma et al. [250], a set of 60 patients with receptor-positive primary 
breast cancers were treated with tamoxifen alone. The results from gene expression profiling of the 
extracted tumor tissues before therapy indicated that the homeobox gene (HOXB13) was over-expressed 
in patients who experienced disease recurrence, whereas the interleukin-17B receptor gene (IL-17BR) and 
EST gene were over-expressed in those with no evidence of recurrence after a 5-year treatment period. 
The investigators evaluated the prognostic utility of each of these three genes by itself and in combination 
with genes that have opposing patterns of expression between the two classes. Results from t-test and 
ROC analyses revealed that a two-gene ratio of HOXB13 over IL-17BR had a stronger correlation with 
treatment outcome than any of the genes alone with AUC values reaching 0.84, and was able to 
accurately predict tumor recurrence in adjuvant tamoxifen-treated patients  
 
This observation was also confirmed in real-time quantitative PCR analysis, where the predictive 
accuracy of the two-gene ratio was 81%. Furthermore, the expression ratio of HOXB13 over IL-17BR 
outperformed existing biomarkers for prognosis of breast cancer, such as patient age, tumor size, grade, 
and lymph node status. In this study pre-dating any formal RXA classification approaches, Ma et al. [250] 
demonstrated the utility of a two-gene expression biomarker in identifying a subset of patients with early-
stage ER-positive breast cancer who are at a risk for tumor recurrence even with tamoxifen therapy. Such 
a biomarker provides a potential means to identify patients appropriate for alternative therapeutic 
regimens in early-stage breast cancer. 
 
Comparative Analysis of TSP and k-TSP Performance in Cancer Classification 
 
Geman et al. [243] introduced the TSP method and demonstrated its efficacy on several gene expression 
datasets involving breast, prostate and leukemia cancers. The phenotype classification problems 
considered were: (i) predicting the status of lymph nodes (affected vs. non-affected) in patients with 
breast tumors using data from [255]; (ii) classifying sub-types of leukemia (AML vs. ALL) using data 
from [256]; and (iii) distinguishing prostate tumors from normal profiles using data from [257]. The 
reported accuracies for TSP results were based on LOOCV, and comparison to randomly permuted data 
was made to estimate the statistical significance for each classifier. 
 
In predicting the status of lymph nodes in the breast cancer dataset, a cross-validation classification rate 
of 79% was achieved from 49 patient samples. The authors also mention a separate study where estimated 
error rates for these data—based on LOOCV and using a wide variety of common machine learning 
techniques—are summarized for varying numbers of pre-filtered genes [255]. Other methods, more 
complex than TSP and using many more genes, did not result in better classification rates, and the low 
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accuracy observed in all methods applied to date is probably a function of the complexity and similarity 
of the phenotypes being separated. In the case of separating AML from ALL, the TSP classifier correctly 
classified 68 samples out of 72 samples in cross validation. In comparison, the study in Golub et al. [256] 
used a fifty-gene classifier to predict 65 samples correctly out of 72. 
 
In addition to demonstrating improved performance in classifying breast cancer and leukemia samples, 
Geman et al. [243] also investigated the ability of TSP to detect the presence of prostate cancer. In a 
previous study, Singh et al. [257] found a strong correlation between patterns of gene expression of 
prostate cancer and various clinical and pathological aspects of the disease. The top-scoring gene pair 
using the TSP algorithm on their data could discriminate non-tumor versus prostate tumor samples at a 
prediction rate of 95%. Hence, the classification rates using TSP were comparable to the best results 
reported previously in the literature, often incorporating hundreds of genes or more in complex decision 
rules.  
 
The performance of TSP and k-TSP classifiers were compared with those of other machine learning 
methods on 19 gene expression datasets involving human cancers in a study by Tan et al. [116]. The 
study investigated a number of publicly available datasets, with sample sizes ranging from 33 to 327 for 
each disease phenotype within a particular dataset. The collection of datasets comprised various studies of 
human cancer, including colorectal, leukemia, lung, prostate, breast, central nervous system, lymphoma, 
bladder, melanoma, renal, uterus, pancreas, ovary, and mesothelioma. The classification performance of 
TSP and k-TSP was compared to that of decision trees (DT), Naïve Bayes (NB), k-nearest neighbor (k-
NN), support vector machines (SVM), and prediction analysis of microarrays (PAM), which is essentially 
linear discriminant analysis. The TSP and k-TSP techniques were also extended beyond binary 
classification to the multiclass setting, where several well-known aggregation strategies, such as “one-vs.-
all” and “one-vs.-other,” were applied to combine the results of binary sub-problems into one final 
decision rule.  
 
In this study, LOOCV was used in order to estimate the classification rate. The best classifier based on the 
average accuracy for the binary classification problems used in this study was k-TSP (92.01%), followed 
by SVM (91.18%), PAM (88.91%), and TSP (88.26%). The differences in accuracies were small, so it 
was concluded that all four methods perform classification similarly. The authors also elucidate the 
biological meaning of the classifiers by showing the connections between the genes in the markers and 
their corresponding cancer types. For the multiclass problems, TSP achieved an average accuracy of 
85.12% over 10 problems, somewhat less than PAM (88.50%) and SVM (88.10%), which performed the 
best overall but used hundreds or thousands of genes.  
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In the initial variant of RXA, Geman et al. [243] showed that the TSP classifier provides decision rules 
that are highly accurate in binary classification problems and involve very few genes. Tan et al. [116] 
compared the TSP and k-TSP approach to other machine learning techniques on a broad source of human 
cancer gene expression data. The performance of TSP and k-TSP on both binary and multiclass problems 
were comparable to those of the other techniques, while no single method was found to have the best 
performance across all datasets. TSP and k-TSP were thus shown to have comparable accuracy to state-
of-the-art methods, involve fewer genes and yield transparent, context-independent classifiers that are 
invariant to most forms of data normalization. 
 
Specific Cancer Studies Using TSP or k-TSP 
 
TSP-based classification methods have been applied to a number of specific cases of predictive studies in 
cancer. These studies can be broadly divided into those that identify classifiers for disease diagnosis and 
studies that develop relative expression classifiers for disease prognosis. Specifically, diagnosis can refer 
to determination of the presence or absence of disease, the particular sub-type of a disease, or in some 
cases the stage of disease. In contrast, prognosis aims to predict the outcome of patients with the disease. 
Examples of disease prognosis include response to treatment, survival time, and tumor metastasis. 
Importantly, a number of the studies presented here demonstrate not only the power of TSP methods to 
accurately classify microarray profiles, but also their utility for integrating microarray datasets from 
different sources and even across different measurement technology platforms. 
 
Gene-pair Classifiers for Diagnosis 
 
Gastrointestinal stromal tumors (GISTs) and leiomyosarcomas (LMSs) are common mesenchymal tumors 
with similar phenotypic features. A whole-genome gene expression study of 68 well-characterized tumor 
samples identified a two-gene relative expression classifier using TSP that distinguished GIST and LMS 
with 99.3% accuracy on microarray samples and 97.8% accuracy in cross validation [258]. The classifier, 
which predicts GIST when OBSCN > C9orf65 and LMS otherwise, was validated using RT-PCR on 20 
samples from the original dataset and on 19 independent samples, achieving 100% accuracy. 
Immunostaining for the Kit protein marker is currently the best test to differentiate GIST and LMS. Using 
expression of c-Kit to classify samples (with a cutoff determined by 1D linear discriminate analysis) 
achieved only 87.3% accuracy. That is, as some GIST samples have low Kit expression and some LMS 
samples have high Kit expression, testing for levels of the protein marker was more prone to error than 
predictions based on the OBSCN/C9orf65 expression ratio. 
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The TSP classification method is invariant to standard procedures for monotonic data normalization, as it 
relies only on the ranks of gene expression values within the microarray. As such, using TSP for 
classification enables the integration of microarray profiles from multiple datasets, thereby increasing the 
sample size of the training data and the predictive potential of the classifiers. Xu et al. [247] identified a 
TSP marker for prostate cancer (HPN > STAT6) that achieves high accuracy, sensitivity, and specificity 
on two datasets from different platforms. Performance of the HPN-STAT6 TSP marker—trained on 
integrated microarray data—was better than other TSP classifiers trained on individual datasets. In 
training the classifier, three microarray datasets from different prostate cancer studies were integrated and 
TSP was applied to analyze both individual and integrated datasets. It was found that TSP markers vary 
between individual datasets, but as more samples are added to the integrated training dataset, TSP 
selection becomes consistent. Stability analysis was also performed to calculate the appearance frequency 
of markers (i.e., how often the same TSP markers were selected) when samples were randomly removed 
from the dataset. The TSP marker was tested on an independent cross-platform dataset, comprising 
prostate tumor expression values from both Affymetrix and spotted cDNA platforms. Samples in the 
independent test set were classified with 93.8% accuracy, 91.7% sensitivity, and 97.7% specificity. 
 
Gene-pair Classifiers for Cancer Prognosis 
 
Xu et al. [259] integrated three independent microarray datasets containing 358 total samples for 
prediction of distant metastases in breast cancer. All samples in the integrated dataset were obtained from 
lymph-node-negative patients who had not received adjuvant systemic treatment. Gene expression data 
was directly merged using 22,283 probe sets on the Affymetrix HG-U133A microarray, and the top 200 
“features” were selected as gene pairs with the highest TSP scores. In accordance with clinical treatment 
guidelines defined by the St. Gallen (Switzerland) expert consensus and the NIH, the goal of the authors 
was to achieve the highest possible specificity while maintaining high sensitivity (~90%). The optimal 
signature size (80 pairs, 112 distinct genes) was determined in k-fold cross validation, and a likelihood 
ratio test (LRT) for classification based on this signature achieved 88.6% sensitivity and 54.6% specificity 
in an independent external test set of 154 samples. Because the LRT assumes statistically independent 
gene pairs, the decision rule amounts to weighted voting among the gene pair classifiers and hence is very 
similar to k-TSP. 
 
Over-expression of the Src tyrosine kinase in pancreatic cancer is thought to play a significant role in 
tumor development and progression. The in vivo efficacy of an orally active small molecule Src inhibitor 
AZD0530 was investigated in a collection of pancreatic tumor xenografts [260]. The k-TSP algorithm 
was applied to gene expression profiles from the tumors in order to identify predictive biomarkers of 
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response to AZD0530. Tumor growth index (TGI) was used to morphologically classify xenografts as 
sensitive (TGI < 50%) or resistant (TGI > 50%) to AZD0530 treatment. In the training set of 16 
xenografts (3 sensitive, 13 resistant), the TSP classifier LRRC19 > IGFBP2 most accurately predicted 
cases as sensitive (and correspondingly predicted cases as resistant when LRRC19 ≤ IGFBP2).  
 
The k-TSP classifier achieved an estimated LOOCV accuracy of 97.8% on the microarray dataset. The 
two-gene predictor was tested and validated on eight independent xenografts not included in the original 
training set and achieved an overall accuracy of 87.5%, specificity of 83.3%, and sensitivity of 100%. 
RT-PCR was performed on the two genes in the eight independent xenografts, showing the relative 
expression of LRCC19 and IGFBP2 was the same as measured by microarray gene expression in all 
cases. This stability across different measurement platforms is critical for application in the clinic and 
represents an advantage of methods based on RXA. 
 
A two-gene expression ratio (RASGRP1/APTX) has been found that accurately predicts response to the 
drug tipifarnib in patients with acute myeloid leukemia (AML) [261]. The TSP algorithm was applied to 
transcriptional profiles of bone marrow samples from newly diagnosed AML patients—including 13 
responders and 13 patients with progressive disease, achieving 92.3% sensitivity and 100% specificity 
(96% accuracy) in LOOCV. External validation of the two-gene classifier was performed in an 
independent dataset of 54 samples from patients with relapsed or refractory AML (10 responders, 44 with 
progressive disease). When applied to the independent test set, the classifier predicted tipifarnib response 
with sensitivity of 80% and specificity of 52.3%. This reduction in accuracy compared to LOOCV may 
derive from the initial very small sample set not being sufficient to represent the amount of variance in the 
population, and thus further data collection and classifier development is needed. Still, the results are 
encouraging considering the subtle difference of the phenotypes being considered and the small amount 
of training data. 
 
In another study, Weichselbaum et al. [262] applied k-TSP to a previously determined gene expression 
signature—the IFN-related DNA damage signature (IRDS)—in order to develop a therapy-predictive 
marker of adjuvant chemotherapy for metastatic breast cancer. 78 breast cancer patients were divided into 
two IRDS status groups (IRDS(+) and IRDS(–)) using hierarchical clustering of microarray data. The k-
TSP classifier was trained using 49 genes in the IRDS along with 534 previously-defined intrinsic breast 
cancer genes, with the optimal number of gene pairs determined using 10-fold cross validation. Each of 
the seven selected gene pairs in the k-TSP classifier contained one IRDS gene and a second gene for 
comparison. Classification was based on a majority vote, where samples were classified as IRDS(+) if 
expression of the IRDS gene was higher than the other gene in at least four of the seven pairs.  
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For the purpose of employing a non-binary measure for survival analysis, the number of positive-scoring 
gene pairs was used to define a TSP IRDS score. Specifically, the sum of pair-wise comparisons in which 
the IRDS gene was more highly expressed defined an ordinal scale from zero to seven, with seven 
representing the most IRDS(+)-like pattern. To examine the IRDS as a predictive marker for therapy 
outcome, a dataset of 295 patients with early stage breast cancer was analyzed based on the TSP IRDS 
score. A multivariable Cox proportional-hazards model for metastatic risk when an interaction with 
chemotherapy is considered revealed a hazard ratio of 1.2—signifying a 1.2-fold increased risk of 
metastasis for each incremental increase in the TSP IRDS score from 0 to 7. These statistically significant 
results suggested that an association of the IRDS with clinical outcome depends on the use of adjuvant 
chemotherapy. 
 
Broad Application of TSP in Disease Diagnosis and Prognosis 
 
A more recent study has shown that two-transcript classifiers have the potential to reliably classify 
diverse human diseases [263]. In this study, the investigators sought to assess the effectiveness of the TSP 
approach in the identification of diagnostic classifiers in a number of human diseases including bacterial 
and viral infection, cardiomyopathy, diabetes, Crohn’s disease, and transformed ulcerative colitis through 
analysis of both local diseased tissue and the immunological response assayed through blood-borne 
leukocytes. The results of this study showed that several diseases of solid tissues could be reliably 
diagnosed through TSP classifiers based on the blood-borne leukocyte transcriptome. The TSP method 
identified multiple predictive gene pairs for each phenotype, with LOOCV accuracy ranging from 70 to 
nearly 100 percent. Performance compared favorably with that of pre-existing transcription-based 
classifiers, and in some cases approached the accuracy of current clinical diagnostic procedures. Thus, 
this study provided further evidence that the TSP classifier represents a simple yet robust method to 
differentiate between phenotypic states based on gene expression profiles of diverse human pathologies. 
The experimental simplicity of this method results in measurements that can be easily translated to 
clinical practice. 
 
Beyond TSP and k-TSP 
 
Top-Scoring Pair of Groups  
 
In an effort to identify a robust common cancer signature, Xu et al. [117] performed a large-scale meta-
analysis of cancer gene expression datasets in order to identify a universal cancer signature and validated 
their signature using a variant of RXA to separate cancer from normal samples across a wide range of 
cancers. More specifically, the authors integrated nearly 1,500 microarray gene expression profiles from 
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26 published cancer datasets across 21 major human cancer types using two different Affymetrix 
microarray platforms. Michiels et al. [264] had shown that molecular signatures are strongly dependent 
on the samples in the training data and advocated the use of repeated random sampling for signature 
validation. In [117], the authors applied an RXA method, referred to as the top-scoring pair of groups 
(TSPG) classifier, combined with a repeated random sampling strategy to identify of a common cancer 
signature consisting of 46 genes. The TSPG classifier is an extension of the TSP classifier from two 
individual genes to two groups of genes. Being an RXA method, it is based entirely on the internal 
ranking of the genes in the signature. The signature is divided into two disjoint groups, and the average 
rank is computed for each group and two averages are compared. The decision rule is again maximum 
likelihood; to choose the class for which the observed ordering between the two rank averages is most 
likely. It can also be shown that TSPG is a special case of k-TSP, where k is the product of the two group 
sizes. Given a new expression profile, the classifier was found to discriminate most human cancers from 
normal tissues, including a validation on six different independent test datasets generated from different 
Affymetrix microarray platforms. Upon further validation, this cancer signature may be used to improve 
understanding of cancer pathogenesis and therapeutic targets, and hence lead to the development of 
effective treatment regimens. 
 
Top-Scoring Triplets 
 
Lin et al. [244] proposed an extension of TSP which bases prediction entirely upon the relative expression 
ordering among three genes, referred to as the “top-scoring triplets” (TST). The decision rule is to select 
the class, which makes the observed ordering the most likely. In many cases, one gene serves as a 
“reference” whose expression falls between the expressions of two differentially expressed genes. The 
objective is to achieve a more discriminating decision mechanism than TSP but without sacrificing 
interpretability. The investigators explored the different roles the three genes play in the decision 
mechanism from previous cancer studies, and also applied this methodology to two problems in breast 
cancer: a cross study validation based on predicting ER status and a clinically relevant application to 
predicting germ-line BRCA1 mutations. Further analysis on protein-protein interactions among the 
triplets of genes aided in understanding the biological roles of the classifiers. 
 
 
Conclusions and Future Directions 
 
The advent of high-throughput measurement technologies for the comprehensive, rapid, and inexpensive 
detection of biomolecular signatures in human cells, tissues, and serum has led to the generation of a 
tremendous amount of raw, unprocessed information. However, analyzing and interpreting these data in 
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order to enhance our understanding of human health and genetic diseases (i.e., cancer) continues to be a 
challenge in the scientific community. In the case of gene expression microarray data, standard statistical 
learning methods have been used to identify decision rules that can accurately distinguish disease 
phenotypes. These techniques have been shown to produce accurate classifiers, but still lack the 
convenience and simplicity desired for extracting any underlying biological rationale for the decision 
rules.  
 
In this chapter, I have provided a detailed description of the concepts and methodologies of the TSP and 
k-TSP classifiers, two bioinformatics techniques for gene expression-based molecular classification based 
on the analysis of relative expression values. Due to the simplicity of the classifier and ease of biological 
interpretation, as well as its independence to data normalization and parameter fitting, the TSP and k-TSP 
methods have been applied in several studies to perform molecular classification of various pathologies, 
primarily cancer. These methods, as I have shown above, display highly accurate classification 
performance in distinguishing a broad range of disease phenotypes (e.g., cancer vs. normal), cancer 
subclasses (e.g., AML vs. ALL, GIST vs. LMS), disease outcomes (e.g., metastasis, survival), and diverse 
human pathologies assayed through blood-borne leukocytes. I have also shown that natural extensions of 
the basic TSP and k-TSP methods can incorporate more genes and allow for indirect microarray data 
integration and hence large-scale meta-studies. Further work on RXA includes the use of biological 
network information (e.g., as described in Chapter 4 and Chapter 5) for phenotype classification and 
biological discovery as well as decision tree-based strategies for classification of multiple disease 
phenotypes. 
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Chapter 3 Figures 
 
 
 
Figure 3.1. Schematic overview of phenotype classification with the top-scoring pair (TSP) 
algorithm in cross validation. 
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Chapter 4. Identifying Tightly Regulated and Variably Expressed Networks by Differential 
Rank Conservation (DIRAC)4 
 
A powerful way to separate signal from noise in biology is to convert the molecular data from individual 
genes or proteins into an analysis of comparative biological network behaviors. One of the limitations of 
previous network analyses is that they do not take into account the combinatorial nature of gene 
interactions within the network. In this chapter, I report here a new technique, Differential Rank 
Conservation (DIRAC), which permits one to assess these combinatorial interactions to quantify various 
biological pathways or networks in a comparative sense, and to determine how they change in different 
individuals experiencing the same disease process. I drove the development and implementation of 
DIRAC and analysis of results, with constructive input from Don Geman from Johns Hopkins University 
and biological insights from Lee Hood at the Institute for Systems Biology. This approach is based on the 
relative expression values of participating genes—i.e., the ordering of expression within pathway 
profiles—and is part of the RXA family of methods described in Chapter 3. DIRAC provides 
quantitative measures of how network rankings differ either among networks for a selected phenotype or 
among phenotypes for a selected network. I examined disease phenotypes including cancer subtypes and 
neurological disorders and identified networks that are tightly regulated, as defined by high conservation 
of transcript ordering. Interestingly, I observed a strong trend to looser network regulation in more 
malignant phenotypes and later stages of disease. At a sample level, DIRAC can detect a change in 
ranking between phenotypes for any selected network. Variably expressed networks represent statistically 
robust differences between disease states and serve as signatures for accurate molecular classification, 
validating the information about expression patterns captured by DIRAC. Importantly, DIRAC can be 
applied not only to transcriptomic data but also to any ordinal data type. 
 
 
Network Expression Analysis and Differential Rank Conservation 
 
Molecular signatures based on the measured abundance of biomolecules (e.g., mRNA, proteins, 
metabolites) have the potential to discriminate among disease subtypes, to predict clinical outcomes, or to 
provide insights into the mechanistic underpinnings of disease progression. Moreover, with sufficient 
data, these signatures begin to enable the identification of perturbed networks that reflect core aspects of 
the disease process—and thus could provide insights into functionally relevant drug targets as well as new 
approaches to diagnostics [7, 139]. However, distinguishing signal from noise in high-throughput data 
such as mRNA microarray experiments presents a significant challenge. This noise commonly results 
                                                     
4 This chapter includes material that was reproduced with permission from the following publication: Eddy, J.A., 
N.D. Price, and D. Geman. 2010. Identifying tightly regulated and variably expressed networks by Differential Rank 
Conservation (DIRAC). PLoS Computational Biology. 6(5):e1000792. (all sections). 
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from technical issues in data production and the integration of datasets from different platforms, 
laboratories, or even experiments within a lab. Noise in high-throughput data also stems from biological 
variability in the sources, such as genetic polymorphisms, different stages of the biological process, 
disease stratification, and stages of disease progression. In the study of human disease processes, this 
variability poses a unique hurdle as there are often only data for a single point in time; when comparing 
data between individuals who appear to have the same disease, one does not know whether the observed 
differences reflect disease subtypes or different stages for a single disease type.  
 
A fundamental tenant of systems approaches to biology and medicine is that dynamically changing 
biological networks mediate physiological, developmental, and disease processes, and that the key to 
understanding these processes is translating network dynamics into phenotypes. As such, a powerful 
method to mitigate some forms of biological noise (hence increasing the utility of high-throughput data as 
a diagnostic and scientific tool) is to convert the molecular data from individual genes or proteins into an 
analysis of comparative biological network behaviors. Typically, studies search for a small number of 
individual genes whose differential expression is highly correlated with phenotypic changes. However, 
malignant phenotypes in many diseases arise from the net effect of interactions among multiple genes and 
other molecular agents within biological networks. For example, cooperating oncogenes interact 
synergistically to evade tumor suppression mechanisms such as cell-cycle arrest and apoptosis [2, 5]. The 
combinatorial nature of such disease-induced perturbations leads to a highly complex picture of the 
underlying biological processes. As such, the biological insight gleaned from the expression patterns of 
individual genes is often limited. Other pitfalls associated with individual gene expression analysis have 
been proposed and discussed elsewhere [7, 239, 265].  
 
The importance of studying network behavior—evident in most phenotypes, disease or otherwise—is 
particularly well documented for cancer. Research has linked modulated function on the level of either 
metabolic networks [41, 43, 266] and/or signaling networks [267-269] to cancer hallmarks including 
angiogenesis, increased growth, metastasis, and evasion of immune detection. Similarly, recent global 
genomic analyses in glioblastoma multiforme [270, 271] and pancreatic cancers [272] have revealed both 
varying numbers and frequencies of genetic alterations within distinct core networks of each disease. In 
light of these findings, microarray data analysis methods have begun to shift towards identifying 
biologically meaningful pathways or networks. One can consider all pathways to in fact be part of 
interconnected biological networks, and henceforth in this chapter, I use the term network rather than 
pathway. In general, network regulation controls the expression levels of related genes responding to 
specific conditions. Existing tools for network-based expression analysis commonly investigate 
informative patterns of up-regulation or down-regulation (i.e., increases or decreases in expression) of 
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genes in different disease states. For example, the widely used gene set enrichment analysis (GSEA) 
platform identifies networks that are significantly enriched for individual genes that are highly correlated 
with a phenotype [128, 239]. Other methods employ a single statistic to represent the collective activity of 
a network (e.g., mean or median gene expression) [7, 134]; perturbed levels of network activity (i.e., 
collective up- or down-regulation) are then examined to identify those networks most differentially 
expressed between phenotypes. These frameworks have been applied to diverse cancer systems and serve 
as a robust source of biological discovery [7, 9].  
 
Studying cellular regulation of networks in terms of “unidirectional” changes may, however, overlook 
subtle, yet influential, changes in the relationships among the genes within a network. This drawback 
directly reflects the combinatorial operation of genes in networks, in which the actions of one gene 
greatly influences the actions of other genes. By accounting for these combinatorial interactions we can 
begin to alleviate the signal-to-noise issues in disease-perturbed networks (as well as dynamically 
changing networks mediating physiology or development). In particular, even the elementary interactions 
captured by the relative orderings among two or three genes have been shown to provide powerful 
biomarkers for separating phenotypes [261, 262, 273]. With methods that aim to identify statistically 
significant up- or down-regulation of genes or networks, results will also depend largely on the context of 
the microarray experiment. Cellular regulation in a case with a number of up- or down-regulated genes in 
one phenotype versus another manifests as an increase in absolute expression levels above some 
threshold, relative to all other genes on the microarray. Even when thresholds are tuned to produce 
statistically significant results, the findings are still based on indirect measurements, (i.e., fluorescence) 
and therefore may depend heavily on the experimental set up, type of data normalization and other 
factors. In addition to the technical limitations of microarray experiments, biological context can greatly 
impact results. For instance, if nearly all genes are differentially expressed between two phenotypes, then 
no single network will be statistically “enriched” for change. It is also possible that neither individual 
network genes nor any network as a whole will display notable over- or under-expression in response to 
environmental or disease-related stimuli. The importance of accounting for combinatorial gene 
interactions again becomes clear, and to do so without need to reference all of the genes on the 
microarray.  
 
I led the development a new method called Differential Rank Conservation (DIRAC), which considers 
combinatorial behavior and provides quantitative measures of how network expression differs within and 
between phenotypes. The DIRAC approach assesses cellular regulation of a network in the context of the 
relative levels of expression for participating genes. For each microarray, the expression values of the 
network genes are ordered from highest expression (ranked first) to lowest expression (ranked last); 
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regulation is then quantified entirely by the rankings of genes within a selected network. Consequently, 
DIRAC identifies and measures network-level perturbations from a completely novel perspective, namely 
the “combinatorial comparisons” of network genes as opposed to increases or decreases alone, allowing 
one to study how this ordering changes in different conditions—and thus begin to infer the consequences 
of combinatorial gene interactions. As a result, this approach has two key advantages over tools that 
measure absolute changes in expression levels. First, it accounts for gene-gene interactions; second, the 
results do not depend on the other genes on the microarray or on the method of normalization used. These 
are both critical points in dealing with signal-to-noise issues. Notably, as DIRAC treats each network 
independently, it can still identify perturbed networks even when every gene on the microarray is 
differentially expressed (in contrast to enrichment measures).  
 
The DIRAC strategy for representing network rankings uses pairwise comparisons of gene expression 
levels. Such pairwise comparisons can yield two-gene predictors with simple decision rules for 
classification of expression profiles [116, 274]. These decision rules have in turn resulted in highly 
accurate two-gene diagnostic classifiers based on relative expression reversals that have proven effective 
for molecular identification of cancer [116, 261, 262, 273, 274]. DIRAC extends the relative expression 
reversal concept to networks. However, analyzing sample-to-sample changes for every possible distinct 
ordering of gene expression values within a network is not computationally feasible; there are simply too 
many possible orderings, i.e., permutations. Knowing the states of all pairwise orderings is equivalent to 
knowing the full ranking, which motivates this particular representation. For each distinct pair of genes 
within a network, we consider a binary variable indicating whether or not the mRNA abundance of the 
first gene is less than that of the second gene; in fact, we restrict attention to the probability of this event 
within a phenotype for each pair of genes. In this way, we avoid the combinatorial complexity of 
permutations and represent the “expected” ordering of network genes for a given phenotype as a binary 
template. Unlike the probabilities of full orderings, pairwise frequencies are reliably estimated with 
typical sample sizes, while still capturing a great deal of information about network regulation. We 
subsequently compute a matching score to signify how closely each sample’s network ordering matches a 
phenotype-specific template. 
 
We can use DIRAC at the population level to quantify conservation differences between networks for a 
given phenotype. Specifically, DIRAC allows us to use rankings to identify and contrast tightly and 
loosely regulated network types of a single phenotype: 
 
i. a network is considered tightly regulated within its phenotype if the ranks of network genes are 
mostly unchanged among samples;  
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ii. a network is considered loosely regulated if the ranks of network genes are greatly varied 
between samples of the same phenotype. 
 
Tightness of regulation for a selected network is best understood as the allowed variation in gene 
expression levels observed across the population. This offers an advantage over studying up- or down-
regulation only because it indicates the level of control across samples in a population. In this work we 
use the DIRAC approach to identify networks that are tightly regulated in a number of human cancers 
neurological disorders. As networks under tight control in a particular phenotype may be necessary to 
maintain a specific cellular function, tightly regulated networks that change across phenotypes may 
provide insight into processes such as disease progression. 
 
Additionally, DIRAC can be applied at the sample level to identify conservation differences between 
phenotypes for a specified network. At this level the DIRAC method can identify variably expressed 
networks that reveal statistically robust differences between disease states, leading to highly accurate 
classification of expression profiles from various diseases. When used to separate expression profiles the 
DIRAC method is noteworthy because it (i) is independent of microarray data normalization; (ii) results 
in a simple yet efficient classifier for phenotype distinction; and (iii) appears to be comparable in 
accuracy to state-of-the-art classification methods. Learning the regulation of gene rankings within 
different states allows us to discover molecular signatures composed of related genes that distinguish 
phenotypes, identify networks most involved in disease transitions, and assist identification of potential 
therapeutic targets. Importantly, while I focus on gene expression in the present study, the method can be 
generalized to any ordinal dataset, and thus can be applied to such biological data types as proteomics, 
gene copy number, chromosomal position, and so forth. 
 
 
Overview of DIRAC Methods 
 
The DIRAC approach was used to evaluate regulation of gene ordering within networks in different 
diseases. For each microarray sample in each phenotype studied, we characterized the ordering of 
network genes (i.e., network ranking) in terms of comparisons between the expression values of pairs of 
genes. Based on the comparison statistics, we defined a rank template for each network and phenotype 
representing the expected (i.e., most common) pairwise ordering of gene expression for that network in 
that phenotype. We employed a simple measure—a rank matching score (R)—to determine how well the 
network ranking in each individual sample (i.e., expression profile) matched the ordering defined in the 
rank template. Averaging R over all samples within a phenotype yields a network-specific rank 
conservation index (μR), which represents how well, on average, all samples in the same phenotype match 
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the corresponding rank template. Alternatively, comparing two rank matching scores for the same sample 
leads to a highly discriminating rank difference score (Δ) that allows one to determine the most variably 
expressed networks between two phenotypes. The calculation of these quantities is illustrated in Figure 
4.1. 
 
Several prototypical scenarios arise from these measures. In one scenario (Figure 4.2, left), conservation 
indices are used to measure the consistency with which network rankings are maintained in a population, 
and are used to identify tightly regulated networks in each phenotype. One situation, where all samples 
have similar network rankings, yields a large rank conservation index and indicates the network is tightly 
regulated. A second situation, where the ordering of network genes is highly varied, yields a small rank 
conservation index and indicates the network is loosely regulated. In a second prototypical scenario, the 
DIRAC method detects changes in ranking (i.e., shuffling of gene expression values) between phenotypes 
for a selected network (Figure 4.2, right). The top networks selected by DIRAC based on the difference 
score can be used to classify gene expression profiles by phenotype. 
 
We first applied DIRAC to investigate network rankings using gene expression profiles obtained from 
patients with different stages of prostate disease. The gene expression data, originally reported by Yu et 
al. [275] and publically available in the NCBI Gene Expression Omnibus (GDS2545), contains 108 
human prostate samples: 18 samples of normal prostate tissue (NP) from organ donors, 65 primary 
prostate tumor (PT) samples, and 25 metastatic prostate tumor (MT) samples. The findings for normal 
prostate and prostate cancer samples presented below represent the main features of the DIRAC method 
and can be similarly obtained for any disease expression data.  
 
In addition to the more detailed prostate cancer analysis, we examined a number of other disease 
phenotypes including cancer subtypes and neurological disorders, and we identified tightly regulated and 
variably expressed networks in each. For each dataset, we grouped expression levels of genes into 248 
human signaling networks, defined according to the BioCarta gene sets collection in the Molecular 
Signatures Database (MSigDB) [239]. In order to ensure that the networks examined were as complete as 
possible, we used gene synonym information from NCBI to replace unmatched names in each dataset 
with those belonging to networks in the BioCarta collection. This step led to an average increase of 5% in 
the fraction of network genes (1296 total across 248 networks) for which a corresponding expression 
value was found. 
 
 
Population-Level DIRAC 
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The population-level analysis is centered on the rank conservation index (μR), defined for each network 
and each phenotype. This index represents the degree of conservation in the rankings of the expression 
levels of the network genes, averaged over samples of the phenotype. 
 
Tightly Regulated Networks in Normal Prostate and Cancerous Prostate 
 
For a given phenotype, the extent of gene ranking conservation within networks will vary across 
networks. The ten most tightly regulated networks in normal prostate (NP), primary prostate tumors (PT), 
and metastatic prostate tumors (MT), as measured by rank conservation indices, are shown in Table 4.1. 
Large rank conservation index values indicate similar gene orderings among all samples of each 
phenotype in these networks, and hence tight regulation. This suggests that the combinatorial gene 
interactions in each network are quite similar among different patients.  
 
Identifying networks that are tightly regulated in some phenotypes and loosely regulated in others 
suggests that the level of control across samples in a population may change dramatically, reflecting the 
nature of the disease process. While identifying changes in tightness of regulation of networks can 
provide insight into molecular differences between phenotypes, some networks may be tightly regulated 
in all phenotypes examined. For example, we found that the G-protein signaling (GS) network is the most 
tightly regulated network in normal prostate (NP), as well as in primary (PT) and metastatic prostate 
tumors (MT). The GS network comprises major signaling proteins downstream of G-protein coupled 
receptors, including both the catalytic (PRKACA) and regulatory (PRKAR1A) subunits of the cAMP-
dependent protein kinase C (PKC). PKC family members phosphorylate a wide variety of protein targets 
and are known to be involved in diverse cellular signaling networks, such as those associated with cell 
adhesion, cell transformation, cell cycle checkpoint, and cell volume control. In 18 NP samples, the 
pairwise orderings among the six GS network genes matched the corresponding normal prostate rank 
template identically for all 15 pairs in the network (μR = 1.000). Similarly, network rankings in PT 
samples and MT samples matched the respective templates for 98.9% (μR = 0.989) and 99.5% (μR = 
0.995) of all pairwise orderings on average. We also found that a single network ranking was shared by 
the majority of NP samples (100%), PT samples (83%), and MT samples (92%); in particular, therefore, 
the GS network rank template was identical in all three phenotypes. Furthermore, the remaining samples 
in PT and in MT displayed only a single mismatch in pairwise orderings compared to the template.  
 
There are several possible explanations for observing tight regulation of certain network rankings in a 
phenotype. In the simplest case, the genes in a network may be expressed at greatly disparate magnitudes, 
making a change in their relative expression rankings less likely. We can see that this is most likely true 
for the GS and FOSB networks, both of which displayed the highest rank conservation for all three 
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prostate phenotypes. The average gene-to-gene expression variance across all samples for these networks 
fell between 1.14-1.58, roughly three times the average gene-to-gene variance for all 248 networks 
(~0.41). As such, a change in the relative ordering among genes in these networks would require a more 
dramatic change in the expression of individual genes. Networks like GS and FOSB are therefore 
analogous to “housekeeping” genes, as the ranking of genes in each is expected to remain the same in 
most samples. 
 
Alternatively, small variation in ordering—nearly the same ranking in all samples of the same 
phenotype—could indicate that a network is critical to maintaining some specific cellular function. This is 
more likely in cases with less gene-to-gene expression variance within a network; if pairwise orderings 
can be easily altered by small changes in expression but remain consistent, some force such as selective 
pressure might drive the cell to minimize fluctuation in the expression of network genes. We found that 
the SET network is tightly regulated in NP samples, but displays much smaller gene-to-gene variance 
than networks like GS and FOSB. The SET network—also known as the granzyme mediated apoptosis 
pathway—comprises a total of 11 genes (illustrated in Figure 4.3), and is an important cytotoxic T cells 
mechanism for fighting tumors and virus-infected cells [276]. While the SET network displays greater 
variation in ranking among NP samples than GS or FOSB (μR = 0. 945), 16 out of 18 samples show only 
five or fewer mismatches compared to the 55 pairs in the rank template. We hypothesize that expression 
of genes within the SET network is highly consistent in NP samples to maintain proper function of 
cellular defense mechanisms. 
 
Tightly regulated networks in disease phenotypes might also lead to useful hypotheses about cell 
behavior. The RAN network, similar to SET, is tightly regulated across MT samples, and shows relatively 
low gene-to-gene variation within the network. The RAN network contains five genes: regulator of 
chromosome condensation (CHC1), Ras-related nuclear protein (RAN), RAN binding proteins 1 and 2 
(RANBP1 and RANBP2), and RAN GTPase activating protein 1 (RANGAP1). In MT samples, on average, 
the pairwise orderings among the five RAN network genes matched the corresponding MT rank template 
for 96.0% of all pairs in the network (μR = 0.960). This network is involved in the export of mRNA 
transcripts from the nucleus to the cytosol for subsequent translation. Although it is unclear what 
advantage tight regulation of the RAN network may confer upon metastatic prostate tumors, there is 
clearly little variation in network ranking. Importantly, the mutation rates in cancer cells are increased 
200-400 fold—providing ample opportunity for changes to be fixed by natural selection or random 
fixation (if the change is not selectively advantageous or disadvantageous).  
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We can learn more by examining the tightness of regulation for the same network in different phenotypes. 
The SET network in PT samples has a rank conservation index equal to 0.909, which is significantly 
lower than in NP samples (P-value < 0.05); similarly, μR for SET in MT samples is equal to 0.891. As 
seen in Figure 4.3, the decreased network rank conservation in PT and MT is due to a greater number of 
samples with rankings different from the respective templates (i.e., more samples with greater numbers of 
mismatches). The increased variation in network ranking seen in the two stages of prostate cancer might 
indicate that the biological function associated with SET genes (i.e., granzyme mediated apoptosis) plays 
a lesser role in behavior of these cells, and is therefore under looser control. It is also possible that in 
primary and metastatic prostate tumors—obviously more malignant phenotypes compared to normal 
prostate—the SET network becomes deregulated, and that this higher deregulation contributes to its 
malignancy. Alternatively, an increase in mutation rates with malignancy might have resulted in more 
random fixations.  
 
These rank conservation indices estimate population statistics based on limited sample sizes (on the order 
of 20-100, as seen in Table 4.2), and hence some variation is expected even if the true indices were the 
same. For instance, the difference in the rank conservation index for the SET network between NP and PT 
or between NP and MT could be a small-sample effect and would need to be validated with either a larger 
study or by a suitable permutation test (see Deregulation of Network Ranking in Disease section below). 
However, even these small-sample estimates generate specific hypotheses, such as an increase in disorder 
in the more malignant phenotype, which can then be meaningfully explored by examining a variety of 
datasets and phenotypes—discussed in the following sections. 
 
Deregulation of Network Ranking in Disease 
 
As described for the SET network above, certain networks may be tightly regulated in one phenotype, but 
not in another. The SET network appears to be relatively tightly regulated in normal prostate but more 
loosely regulated in both primary and metastatic prostate tumors. Cases such as this represent the 
deregulation of a network in one phenotype relative to another. We used the difference in rank 
conservation index values between phenotypes as the basis for identifying the most deregulated networks. 
For example, in comparing NP samples to MT samples, we first calculated the rank conservation index 
for all networks in both phenotypes. Next, we identified the networks with the greatest absolute difference 
in index values between NP and PT (i.e., highly conserved in one class but not in the other). Based on 
sample permutation tests, we found that 67 out of 248 networks had a significant difference in index 
values (P-value < 0.05; see Detailed Methodology). The network with the largest conservation 
difference—the FIBRINOLYSIS network—was more tightly regulated in NP (μR = 0.891) than in MT (μR 
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= 0.736) (Table 4.3). The FIBRINOLYSIS network comprises 12 genes and breaks down fibrin clots 
formed during coagulation. It has previously been reported that patients with metastatic prostate cancer 
occasionally exhibit enhanced fibrinolytic activities with symptoms of bleeding, epistaxis or other forms 
of hemorrhage [277]. Deregulation of the FIBRINOLYSIS in MT samples might therefore be directly 
linked to malignant features of the disease. However, without further information it is impossible to 
discern whether loose regulation of this network is a causative mechanism in MT, or occurs as a 
downstream effect of some other perturbation in tumor progression. 
 
Upon inspecting the remaining differentially regulated networks between NP and MT, we found that in 
fact, 57 out of 67 significantly deregulated networks identified showed tighter regulation in NP than in 
MT (Figure 4.4J). The strong majority of networks more tightly regulated in the NP (P-value = 5.14x10-8 
from a binomial distribution; see Table 4.4) lends evidence to the theory that deregulation of network 
ranking is in some way related to increased malignancy. As such, the DIRAC approach may be useful 
both in the stratification of disease and/or in assessment of the progression of disease. To explore this 
hypothesis further, we examined a number of gene expression datasets available for public download 
from the NCBI Gene Expression Omnibus (Table 4.2). These datasets included expression profiles from 
multiple cancers such as breast, ovarian, and blood (leukemia), as well as diseases of the brain/nervous 
system, skin, and intestinal tract (note: the leukemia datasets G and H were excluded from this particular 
comparison, as there is no clear evidence for which subtype—AML or ALL—is more malignant). We 
repeated the procedure described for NP and MT for each binary phenotype comparison from the 
expression data. In all but one case out of nine, the less malignant phenotype had a greater number of high 
conserved (tightly regulated) networks (Figure 4.4). That is, a network appears much more likely to 
become deregulated in worse cases of disease. Importantly, the dataset for the one exception—comparing 
Marfan syndrome and normal fibroblasts—contained expression values for only ~4,000 genes (compared 
to 20,000 or more in most of the other datasets). Due to the small number of genes, many of the networks 
contained significant caps, which may have produced less robust results. Still, the overall trend seen in 
Figure 4.4 suggests that in malignant phenotypes, networks are often more loosely regulated, with greater 
variation in expression ranking of participating genes from sample to sample. The global pattern of 
increased disorder with malignancy highlights the utility of studying gene expression ordering within 
networks, and also reveals a striking phenomenon that could drive future investigation and may lead to 
new understandings of gene expression in disease. 
 
Global Regulation of Networks Across Phenotypes 
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Averaging rank conservation indices over all the networks provides a measure of global regulation of 
networks in different phenotypes. For example, networks in normal prostate are more highly conserved on 
average (0.903) than networks in metastatic prostate cancer (0.884). This difference suggests that the 
more malignant cancer subtype (MT) may have greater overall variation in network rankings among 
different samples. We used the gene expression datasets described above to compare global regulation of 
network rankings among a number of phenotypes. For each phenotype, we calculated rank conservation 
indices for all networks and used the average conservation as a rough measure of how tightly or loosely 
regulated networks tend to be in each case. 
 
We used the average index value to order phenotypes from highest to lowest global conservation. 
Phenotypes with the highest average conservation primarily have tightly regulated networks across 
samples in the population. For example, most networks in non-bipolar cortex and bipolar cortex were 
found to have conservation index values greater than 0.95 (seen as bright colors on the heatmap in Figure 
4.5) for average values of 0.956 and 0.955, respectively. In contrast, many networks in the two breast 
cancer phenotypes (r—responsive to treatment; nr—non-responsive to treatment) have rank conservation 
indexes less than 0.80 (dark colors on the Figure 4.5 heatmap). In this case, the low global 
conservation—average index values of 0.835 and 0.826 in (r) breast cancer and (nr) breast cancer, 
respectively—suggests that network rankings in these disease phenotypes have looser regulation and 
greater variation. Based on a one-way ANOVA, the estimated overall P-value for the ordering of 
phenotypes in Figure 4.5 is zero. 
 
Interestingly, the trend of lower conservation in more malignant phenotypes described in the previous 
section seems to persist even from a coarser, global perspective. For example, networks in the less 
malignant adenoma-like ovarian tumors are more highly conserved on average (0.947) than in more 
malignant carcinoma-like ovarian tumors (0.913). The same was seen when examining all three prostate 
phenotypes, where normal prostate is more tightly regulated overall than primary (p) prostate cancer, 
which itself is more tightly regulated than metastatic (m) prostate cancer. Even for the most highly 
conserved phenotypes (non-bipolar and bipolar cortex) and lowest conserved phenotypes (breast cancers), 
networks are more tightly regulated on average in the less malignant phenotype of each pair. We also 
observed interesting differences observed based on tissue-type, where expression ranking of networks in 
brain and ovarian tissue displayed higher conservation on average than prostate tissue, which is in turn is 
more highly conserved than in blood and in breast tissue. Thus, at least two global trends must be 
considered in evaluating network deregulation: (i) the severity of the disease, and (ii) the tissue of origin. 
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Sample-Level DIRAC 
 
In order to identify variably expressed networks between two selected phenotypes, we designed a rank 
difference score (Δ), calculated for each sample based on rank matching scores. For a particular network, 
this measure indicates the similarity between the ordering of network genes in a sample to the template of 
one class versus the template of the other. The difference score ranges from -1 to 1, with positive values 
suggesting the first phenotype, and negative values suggesting the second, culminating in simple rules for 
classifying an expression profile. Our purpose in introducing the rank difference score was two-fold: (i) to 
identify variably expressed networks between two selected phenotypes; and (ii) to validate the DIRAC 
approach to network identification, and the emphasis on combinatorial interactions, by demonstrating the 
discriminative power of the networks identified. 
 
Variably Expressed Networks in Prostate and Prostate Cancers 
 
As shown in Figure 4.6, this positive versus negative trend holds for most samples in MT and NP across 
all networks. To determine the most variably expressed networks between MT and NP, we (i) defined 
rank templates for each phenotype; (ii) calculated rank matching scores and evaluated the rank difference 
score for each sample; and (iii) chose the networks with the largest estimated classification rate. 
Specifically, the classification rate for a network is defined as the average of sensitivity and specificity for 
predicting sample classes in the training data (i.e., apparent accuracy). 
 
To evaluate whether variably expressed networks represented meaningful differences between MT and 
NP gene expression profiles, we used permutation-based testing to assess the statistical significance of 
estimated network classification rates (see Detailed Methodology). A total of 176 networks significantly 
differentiated between expression profiles of MT and NP (P-value < 0.05), the top ten of which appear in 
Table 4.5. Among these differentially expressed networks, we estimated that only 6.7% (between 11 and 
12 of the 176 total) are likely to have been found by chance rather than based on true differences between 
the phenotypes, as determined by the FDR. 
 
The principal features governing the rank difference score, and also an example of its application to 
molecular classification, are illustrated in Figure 4.7 for the MAPK network, which we identified as one 
of the most differentially expressed networks between normal prostate and metastatic prostate tumors. 
Here, R(xn) denotes the rank matching score for a profile xn, and superscripts indicate the network and 
phenotype of the rank template (e.g., R(MAPK,MT)(xn) represents the rank matching score for a sample when 
compared to the ordering defined in the MT template). The rank difference score is the difference in 
matching score values for a particular sample: R(MAPK,MT)(xn) – R(MAPK,NP)(xn). This measure captures low 
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variance of network ranking within phenotypes, but disparate rankings between phenotypes. The rank 
difference values calculated for the MAPK network for all samples are shown in Figure 4.7, along with 
the corresponding phenotype predictions (i.e., MT where positive, NP if negative). Interestingly, MAPK 
signaling has been previously reported to be involved in the cancerous transformation of prostate cells 
[278, 279]. 
 
DIRAC-based Classification of Disease Phenotypes 
 
The top networks selected by DIRAC based on the difference score (i.e., the single best network for 
separating each different pair of phenotypes) were used to classify gene expression profiles in cross-
validation. Specifically, we used leave-one-out cross validation (LOOCV) to estimate how accurately the 
top networks selected predicted the phenotype of future samples (Figure 4.8). Importantly, all processes 
including defining rank templates, calculating rank difference scores, and selecting the best network were 
done within cross-validation, using only the training samples (i.e., no information from test samples was 
used to train classifiers). For comparison, we selected the top Gm differentially expressed genes—where 
Gm is equal to the number of genes in the top network selected by DIRAC—and used the top-scoring pair 
(TSP) algorithm [116, 245] and support vector machines (SVM) [280, 281] to classify samples in each of 
the datasets. We found that our method performed well in a number of the datasets, with estimated 
accuracies between 92-96% in gastrointestinal sarcoma, ovarian cancer, leukemia, and prostate cancer--
including comparisons between normal prostate and cancer as well as different stages of prostate cancer 
(Figure 4.8). In cases with poor accuracies, such as responsiveness of breast cancer to therapy, bipolar 
disorder, and Marfan syndrome, we observed that other methods also failed to accurately classify 
samples, suggesting that these phenotypes are inherently difficult to separate based on the available 
expression data.  
 
Overall, we found that classification, when restricted to only the genes in the top network (as determined 
by DIRAC), is nearly as accurate as using the overall Gm most differentially expressed genes (in TSP or 
SVM). Our foremost goal was not to propose a new classifier, but to aid in biological discovery and 
hypothesis generation; the classification accuracy simply affirms the robustness of the network rank 
regulation measure. Specifically, the classification experiment validates DIRAC by demonstrating the 
importance of combinatorial interactions: the potential loss of discriminating power in individual genes is 
countered by discriminating interactions.  
 
 
Implications for Systems Medicine 
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Systems medicine approaches assume that disease arises from disease-perturbed biological networks in 
the relevant organ or organs. These disease-perturbed networks alter the envelopes of information that 
they express—and these changes encode the pathophysiology of the disease. Moreover, the altered 
patterns of information can elucidate new strategies for diagnosis or therapy. Future drugs will likely be 
designed to re-engineer disease-perturbed networks to behave in a more normal fashion, or at least to 
abrogate their most deleterious consequences. This will require a new drug target identification approach, 
and re-engineering disease-perturbed networks appropriately will almost always require multiple drugs. 
Likewise, the perturbed nodal points in disease-perturbed networks can be expressed as proteins in the 
blood—where the disease-altered levels of expression may reflect the disease process. These disease-
altered blood proteins will create unique blood fingerprints specific for each disease process, and thus 
provide powerful diagnostics. These advances rely upon the proper identification of disease-perturbed 
networks. To date, most of the evaluation of networks has employed lists of transcripts that are perturbed 
from the levels of their counterparts in normal organs. This listing, as with genome-wide association 
(GWAS) studies, misses the key fact that disease-perturbed networks must be assessed in the context of 
the combinatorial interactions of their nodal components.  
 
Our method is the first approach that begins to account for the combinatorial behavior of interacting 
genes, mRNAs and/or proteins. Using DIRAC-based calculations allows us to begin to assess the key 
disease-perturbed networks that may aid in the approach to diagnosis and therapy. We also stress that 
these methods will almost certainly prove powerful in the stratification of disease types. The example of 
gastrointestinal stromal tumors (GIST) and leiomyosarcomas (LMS), histologically indistinguishable, but 
clearly classifiable by a primitive version of DIRAC, is striking. We believe this will be a powerful 
approach in, for example, distinguishing various types of neurodegenerative diseases, as well as the 
stratification of complex diseases such as Alzheimer’s. Notably exciting, some of the key transcripts used 
in this classification process actually encoded proteins secreted into the blood. Findings of this nature 
could lead to the use of altered blood levels of proteins for diagnosis without the need to sample disease 
tissues. Emerging technologies will make these measurements possible at the single cell level, exposing 
other exciting possibilities for diagnosis using the strategies outline above. We predict the application of 
DIRAC as a powerful clinical tool in the advancing proactive, rather than reactive, new medicine—the 
so-called P4 medicine (predictive, personalized, preventive and participatory)—where blood and single-
cell diagnostics will be the foundation of the P4-medicine revolution.  
 
 
Conclusions  
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In this study, we demonstrated a novel method to identify highly discriminative biological networks based 
on differing patterns of gene expression ranking within networks. These results provide a coarse, but 
meaningful, glimpse into patterns of network regulation for different phenotypes based on combinatorial 
relationships between the involved genes. For example, when comparing two disease states, it appears to 
be very common (although not universal) for network rankings to be more varied—or less tightly 
regulated—in the more pathological disease. This increased disorder associated with malignancy might be 
expected, as mutations and other altered behavior of biomolecules lead to breakdown of typical 
functioning in biological networks. Rank conservation index values calculated in DIRAC represent a 
quantitative means to study and further verify this notion. Importantly, this method not only identifies 
perturbed networks, but does so in such a way that it can classify samples. Thus, predictive accuracy 
becomes a strong measure for the validity of the perturbed network as a reproducible hallmark of the 
disease phenotype. Such high predictive accuracy in classification adds much stronger evidence that 
biologically meaningful network differences are found than only a low P-value or FDR, which simply 
measure how likely the result derives from chance. Measures of global regulation can also give useful 
information for designing research to identify expression-based classifiers of disease. For instance, it 
would be more fruitful to search for clear molecular signatures with tightly regulated phenotypes. In cases 
with mostly loosely regulated networks, the greater variation from sample-to-sample would pose a more 
difficult challenge for identifying reliable classifiers. Studying rank regulation of biologically relevant 
networks thus offers a promising tool for measuring network behavior within and across different 
populations. Looking forward, the results obtained through this approach should provide increased insight 
into phenotypic processes of importance in biology and medicine. 
 
 
Detailed Methodology 
 
The methods and analyses presented here were performed entirely in Matlab. Source code files are 
available for download at http://www.igb.uiuc.edu/labs/price/downloads.  
 
Microarray Data 
 
Given the list {g1, …, gGm} of Gm genes within a network m on a microarray, we let X = (X1, …, XGm) 
denote the corresponding expression profile, where Xi is the expression level of gene gi. Our data then 
consists of a Gm x N matrix; the nth column represents the expression profile xn of the nth sample, n = 1, 
…, N. In addition, each sample is labeled by a phenotype Y ∈ {A, B, …, K}. The labeled training set is F 
= {(x1, y1), …, (xN, yN)}. Expression profiles X and phenotype labels Y are regarded as random variables, 
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and the elements of F represent independent and identically distributed samples from some underlying 
probability distribution of (X, Y).  
 
Our analysis is based entirely on the ranks within each expression profile. With Gm genes, there are Gm! 
possible orderings for the expression values. The networks we consider typically have tens or hundreds of 
genes; consequently, working directly with individual permutations is not feasible. For example, any 
estimated distribution over permutations using training data would be highly singular. Instead, we base 
the analysis entirely on pairwise comparisons.  
 
Rank Template Matching for Networks 
 
Knowing the ordering of the gene expressions within each network expression profile is equivalent to 
knowing all of the pairwise orderings, i.e., whether Xi < Xj or Xi > Xj for each distinct pair of genes 1 ≤ i, j 
≤ Gm within the network m. Evidently, there are Gm(Gm – 1)/2 such pairs. For example, if there are Gm = 4 
genes, then there are six distinct ordered pairs: {(1, 2), (1, 3), (1, 4), (2, 3), (2, 4), (3; 4)}. In order to 
define a template representing the expected ranking of network genes within a phenotype, we consider the 
probabilities Pr(Xi < Xj |Y = k) for each pair of genes gi < gj and for each phenotype k. We estimate these 
probabilities from the training set by computing the fraction of samples in each phenotype for which gene 
gi is expressed less than gene gj. The rank template for a fixed network m and phenotype k is the binary 
vector T(m,k) of length Gm(Gm – 1)/2 where the i,jth component is 1 if Pr(Xi < Xj |Y = k) > 0.5 and 0 if Pr(Xi 
< Xj |Y = k) ≤ 0.5. The calculation of a rank template is illustrated in Figure 4.1. 
 
Given an expression profile xn for the network m, there is then a natural measure for how well the sample 
matches the template T(m,k). The rank matching score of sample n is denoted by R(m,k)(xn) and is defined to 
be the fraction of the Gm(Gm – 1)/2 pairs for which the observed ordering within xn matches the 
template—the orderings expected for phenotype k. See Figure 4.1 for an illustration of a rank matching 
score.  
 
Rank Conservation Indices 
 
Averaging the rank matching score over all the samples in a phenotype k yields a rank conservation index 
denoted by μR(m,k) = E(R(m,k)|Y = k). This index is estimated by averaging the scores R(m,k)(x) over all the 
samples (x, y) in the training set for which y = k. Whereas the rank matching score is a sample-based 
statistic, i.e., it is defined for each expression profile, the rank conservation index is a population statistic. 
The rank conservation index can be seen as a measure of the stability in rankings among the network 
genes in the phenotype. Two extreme cases correspond to (i) pure random shuffling of the expression 
values in the phenotype from sample to sample, in which case μR(m,k) ≈ 0.5; and (ii) all samples displaying 
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exactly the same ordering, in which case μR(m,k) ≈ 1. In general, there are many gene pairs gi and gj which 
are expressed on different scales, and hence xi < xj across nearly all samples and phenotypes. As a result, 
one generally finds μR(m,k) >> 0.5. This index is similar to entropy in the sense that values of μR(m,k) ≪ 1 
indicate a highly disorganized state in which there is a great deal of variation among the rankings in 
phenotype k from sample to sample and values of μR(m,k) ≈ 1 indicate a highly ordered state in which 
samples have very similar, and hence predictable, orderings among the genes. 
 
Rank Difference Scores 
 
Consider two phenotypes Y = A, B, and a fixed network m. If network m is tightly regulated in one 
phenotype, the samples from that phenotype, say Y = A, will have high R(m,A) values on average. But if 
μR(m,k) is large for both k = A and k = B, and if the two rank templates T(m,A) and T(m,B) are significantly 
different, then the samples from phenotype Y = A will generally have low values for the statistic R(m,B) as 
well as high values for the statistic R(m,A), and vice-versa for the samples from phenotype Y = B. We 
capture this phenomenon, namely low variance of network ranking within a phenotype, but high variance 
between phenotypes, with a single statistic calculated for each sample: the difference Δ(m)(xn) = R(m,A)(xn) 
– R(m,B)(xn). Clearly, –1 ≤ Δ(m)(xn) ≤ 1 with positive (respectively, negative) values providing evidence that 
the phenotype of sample n is Y = A (resp., Y = B). As a result, the difference score provides a classifier for 
phenotype identification based on the degree of regulation of the genes in network m. A new sample n is 
predicted to belong to phenotype Y = A if Δ(m)(xn) > 0 and to phenotype Y = B if Δ(m)(xn) ≤ 0. The 
classification rate for network m is then: η(m) = Pr(Δ(m)(X) > 0|Y = A)*Pr(Y = A) + Pr(Δ(m)(X) ≤ 0|Y = 
B)*Pr(Y = B). The calculation of a rank difference score was shown in Figure 4.1. 
 
For example, if Y = A denotes prostate cancer and Y = B denotes normal prostate, and if we assume that 
the two phenotypes are a priori equally likely, then η(m) is simply the average of sensitivity and 
specificity relative to identifying cancer. In order to determine the most variably expressed networks 
between two given phenotypes, we calculate rank templates for each phenotype, evaluate the differential 
score for each sample in the training set and choose the networks with the largest estimated classification 
rate. 
 
One previously reported method, k-TSP, classifies expression profiles based on k pairs of genes with the 
most significant expression reversals among all assayed genes [116]. The classifier based on the rank 
difference score is also based on k pairs of genes, with k equal to the distance between the two rank 
templates. To see this, notice that upon computing the difference Δ(m)(xn) for pathway m and phenotypes 
A and B, the gene pairs (i,j) for which T(m,A)(i,j) = T(m,B)(i,j) cancel out. The DIRAC-based classifier 
therefore reduces to voting among the gene pairs whose probabilities straddle 0.5—i.e., satisfy Pr(Xi < Xj 
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|Y = A) < 0.5 < Pr(Xi < Xj |Y = B) or vice versa. However, these k pairs of genes are those in the “top-
scoring network” as determined by DIRAC rather than the most discriminating k pairs overall (as would 
be identified by k-TSP). 
 
Significance Testing 
 
Procedures for estimating statistical significance are described below for metastatic prostate tumors (MT) 
and normal prostate (NP). Identical procedures were used for all binary phenotype datasets studied. 
 
I. Deregulated Networks Based on the Difference in Rank Conservation Indices 
 
Under the null hypothesis that no systematic difference in gene expression profiles exists between MT 
and NP, (i) the original phenotype labels were randomly re-assigned to samples, and rank conservation 
indices were calculated for all networks in each phenotype; (ii) the absolute difference in rank 
conservation index values between the two phenotypes was calculated for each network (i.e., θ(m) = 
|μR(m,MT) – μR(m,NP)| for the mth network); (iii) the first two steps were repeated for 1,000 permutations to 
generate a null distribution of rank conservation difference values; and (iv) the significance level for θ(m) 
representing deregulation of a network between MT and NP was measured as the probability of observing 
differences in rank conservation greater than or equal to θ(m) in the null distribution. 
 
II. Classification Rate for Networks Based on the Rank Difference Score 
 
Under the null hypothesis that no systematic difference in gene expression profiles exists between MT 
and NP, (i) the original phenotype labels were randomly re-assigned to samples, and rank difference 
scores were calculated for each sample in all networks; (ii) sample classes in the permuted dataset were 
predicted as MT or NP based on whether the difference score was positive or negative, respectively, and 
scores were assigned to each network as measured by the estimated classification accuracy (i.e., η(m) for 
the mth network); (iii) the first two steps were repeated for 10,000 permutations to generate a null 
distribution of network classification rates; and (iv) the significance level for the η(m) in predicting MT 
and NP profiles was measured as the probability of observing classification rates greater than or equal to 
η(m) in the null distribution. To address the issue of multiple-hypothesis testing, we also estimated the 
false discovery rate (FDR) for each significance level, representing the fraction of our selected features 
which we would expect to be false positives. 
 
Evaluating Classification Performance 
 
We used leave-one-out cross validation to estimate the (generalization) error rate of each classification 
method studied. Importantly, for each classification method tested, all processes were done using only the 
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training samples without including any information from the test sample. Within each iteration of the 
cross validation loop, expression profiles in the original training data F = {(x1, y1), …, (xN, yN)} are 
divided into two groups: a training set (Ftrain) and a test set (Ftest). The classifier is trained on the N – 1 
samples of Ftrain and then used to predict the phenotype of the remaining “left out” sample in Ftest. The 
overall cross validation classification rate after N total train-test divisions and predictions is calculated as 
the average of sensitivity and specificity. Details for training and testing with each type of classifier are 
described below. 
 
I. DIRAC 
 
Rank templates, rank matching scores, and rank difference scores are calculated uniquely for each new 
instance of the training set Ftrain. The single best network is chosen based on the classification rate for 
samples of Ftrain, and the rank templates for this network are then used to assign two rank matching scores 
to the remaining sample comprising Ftest. If the difference in matching scores is positive, the sample is 
predicted to be of phenotype A, otherwise it is classified as phenotype B. 
 
II. TSP 
 
The top-scoring pair (TSP) algorithm is described in detail elsewhere [116]. Here, we first filtered the 
total number of transcripts in Ftrain, keeping only the top Gm most differentially expressed genes (DEGs), 
where Gm is equal to the number of genes in the best network selected by DIRAC. The top features (i.e., 
DEGs) were selected based on the Wilcoxon ranksum test. Searching among all possible pairwise 
combinations of genes in the reduced dataset, we identified a single best pair (Xi and Xj) for which the 
difference |Pr(Xi < Xj | A) – Pr(Xi < Xj | B)| is maximized (or alternatively, |Pr(Xi > Xj | A) – Pr(Xi > Xj | B). 
The phenotype of Ftest is then predicted by comparing the expression levels for this gene pair. 
 
III. SVM  
 
Prior to training a support vector machine (SVM) classifier on the samples of Ftrain, we also filtered down 
to the top Gm DEGs within each cross validation loop, where Gm is equal to the number of genes in the 
best network selected by DIRAC. The SVM was then trained on the expression values of these Gm genes 
using a Gaussian kernel, and then used to predict the phenotype of Ftest. 
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Chapter 4 Figures & Tables  
 
 
 
Figure 4.1. Overview of Differential Rank Conservation (DIRAC) methods. 
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Figure 4.2. Prototypical scenarios observed for networks in DIRAC. 
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Figure 4.3. Example of a tightly regulated network in normal prostate.   
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Figure 4.4. Deregulation of networks in disease.   
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Figure 4.5. Diverse rank conservation of networks across phenotypes.   
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Figure 4.6. Differential rank conservation across all networks for a set of two prostate 
phenotypes.   
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Figure 4.7. Differential rank conservation of the EDG1 network in metastatic prostate 
cancer and normal prostate.   
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Figure 4.8. Classification with DIRAC compared to other methods. 
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Table 4.1. Most tightly regulated networks in normal prostate and primary and metastatic prostate 
tumors, as indicated by rank conservation index values. 
 
Tightly regulated networks in NP 
Network name Num. genes Num. gene pairsa 
Avg. variance 
in NP μR in NP 
GS 6 15 1.328 1.000 
FOSB 4 6 1.141 0.981 
AKAP13 7 21 0.796 0.955 
AGPCR 11 55 0.811 0.955 
RNA 8 28 0.453 0.948 
CACAM 12 66 0.551 0.947 
NDKDYNAMIN 17 136 0.619 0.946 
ETC 8 28 0.350 0.946 
SET 11 55 0.537 0.945 
SKP2E2F 10 45 0.339 0.943 
Tightly regulated networks in PT 
Network name Num. genes Num. gene pairs 
Avg. variance 
in PT μR in PT 
GS 6 15 1.270 0.989 
FOSB 4 6 1.525 0.979 
AKAP13 7 21 0.880 0.960 
ARGININEC 6 15 0.548 0.960 
PLK3 8 28 0.672 0.951 
CDC42RAC 15 105 0.547 0.946 
RNA 8 28 0.489 0.946 
CREM 7 21 0.563 0.944 
BOTULIN 4 6 0.850 0.944 
AGPCR 11 55 0.771 0.943 
Tightly regulated networks in MT 
Network name Num. genes Num. gene pairs 
Avg. variance 
in MT μR in MT 
GS 6 15 1.322 0.995 
FOSB 4 6 1.575 0.980 
CREM 7 21 0.659 0.966 
S1P 6 15 0.465 0.963 
RAN 5 10 0.371 0.960 
SLRP 4 6 1.227 0.960 
BOTULIN 4 6 0.722 0.953 
AKAP13 7 21 0.787 0.947 
SARS 10 45 0.819 0.939 
RAB 10 45 0.441 0.937 
 
aThe number of gene pairs is equal to Gm(Gm – 1)/2, where Gm is the number of genes in the network. 
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Table 4.2. Human disease gene expression datasets studied with DIRAC. 
 
Dataset Ref Samples Tissue type Disease/source (subtypes)a Short nameb 
Subtype  
samples 
A [273] 68 gastrointestinal sarcoma gastrointestinal stromal tumor GIST 37 
    Leiomyosarcoma LMS 31 
B [282] 43 ovarian tumors carcinoma-like ovarian tumor CL ovarian tumor 20 
    adenoma-like ovarian tumor AL ovarian tumor 23 
C [283] 101 skin fibroblasts Marfan syndrome subjects MFS fibroblast 60 
    control subjects non-MFS fibroblast 41 
D [284] 44 head and neck skin cells 
head and neck squamous cell 
carcinoma HNSCC 22 
    normal head and neck skin cells normal head/neck 22 
E [250] 60 primary breast cancer tumor 
patients non-response (cancer 
recurred) to treatment (nr) breast cancer 28 
    
patients responsive (disease-
free) to treatment (r) breast cancer 32 
F [285] 61 
dorsolateral prefontal cortex and 
orbitofrontal cortex Bipolar disorder patients bipolar cortex 30 
    control patients non-bipolar cortex 31 
G [286] 72 blood and bone marrow acute myeloid leukemia AML 1 25 
    acute lymphocytic leukemia ALL 1 47 
H [287] 48 blood and bone marrow acute myeloid leukemia AML 2 24 
    acute lymphocytic leukemia ALL 2 24 
I [275] 83 normal and tumorgenic prostate primary prostate tumors (p) prostate cancer 65 
    normal prostate tissue  normal prostate 18 
J [275] 43 normal and metastatic prostate metastatic prostate tumors (m) prostate cancer 25 
    normal prostate tissue  normal prostate 18 
K [275] 90 prostate tumor metastatic prostate tumors (m) prostate cancer 25 
    primary prostate tumors (p) prostate cancer 65 
 
aFor each set of expression profiles, the two subtypes are listed in order from most to least malignant (e.g., tumor type with 
worst prognosis or cancer versus control).   
bShort names are used to reference specific phenotypes in subsequent figures. 
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Table 4.3. Most differentially regulated networks between three stages of prostate disease. 
 
Differentially regulated networks (PT vs. NP) 
Network name Num. genes Num. gene pairsa μR in PT μR in NP Abs. difference in μR P-value 
TCRA 12 66 0.859 0.928 0.069 5.85E-04 
TCRMOLECULE 5 10 0.871 0.939 0.068 6.69E-04 
EIF2 7 21 0.854 0.915 0.061 1.33E-03 
TERC 6 15 0.877 0.933 0.056 2.29E-03 
NEUTROPHIL 8 28 0.848 0.901 0.053 3.33E-03 
GLYCOLYSIS 8 28 0.879 0.929 0.050 4.57E-03 
ACE2 11 55 0.835 0.885 0.050 4.72E-03 
FIBRINOLYSIS 12 66 0.847 0.891 0.044 9.17E-03 
INTRINSIC 22 231 0.852 0.896 0.044 9.45E-03 
CLASSIC 10 45 0.886 0.930 0.044 9.74E-03 
Differentially regulated networks (MT vs. NP) 
Network name Num. genes Num. gene pairs μR in MT μR in NP Abs. difference in μR P-value 
FIBRINOLYSIS 12 66 0.736 0.891 0.156 -6.66E-16 
EXTRINSIC 12 66 0.716 0.870 0.155 -6.66E-16 
INTRINSIC 22 231 0.761 0.896 0.135 2.02E-05 
CLASSIC 10 45 0.829 0.930 0.100 2.90E-04 
TERC 6 15 0.843 0.933 0.091 6.21E-04 
ION 5 10 0.892 0.806 0.086 8.35E-04 
COMP 14 91 0.832 0.914 0.082 1.20E-03 
NEUTROPHIL 8 28 0.819 0.901 0.082 1.21E-03 
ARF 15 105 0.829 0.911 0.081 1.32E-03 
PEPI 5 10 0.808 0.889 0.081 1.34E-03 
Differentially regulated networks (MT vs. PT) 
Network name Num. genes Num. gene pairs μR in MT μR in PT Abs. difference in μR P-value 
EXTRINSIC 12 66 0.716 0.856 0.140 -6.66E-16 
FIBRINOLYSIS 12 66 0.736 0.847 0.111 8.06E-06 
INTRINSIC 22 231 0.761 0.852 0.091 4.03E-05 
ION 5 10 0.892 0.803 0.089 6.05E-05 
PEPI 5 10 0.808 0.895 0.087 6.85E-05 
ARGININEC 6 15 0.880 0.960 0.080 1.65E-04 
LEPTIN 8 28 0.807 0.727 0.080 1.73E-04 
NOTCH 4 6 0.853 0.931 0.077 2.42E-04 
PLC 8 28 0.800 0.859 0.059 1.74E-03 
BETAOXIDATION 6 15 0.864 0.922 0.058 1.86E-03 
 
aThe number of gene pairs is equal to Gm(Gm – 1)/2, where Gm is the number of genes in the network. 
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Table 4.4. Statistical significance of network deregulation in malignant phenotypes. 
 
Dataset # tighter in less malignant # tighter in more malignant Outcome Binomial P-value 
A 26 0 1 0.00 
B 122 1 1 0.00 
C 13 18 0 0.76 
D 23 6 1 0.00 
E 13 1 1 6.10E-05 
F 9 7 1 0.23 
I 24 6 1 1.62E-04 
J 57 10 1 3.41E-10 
K 39 13 1 6.38E-05 
Total 326 62 8 0.00 
  Binomial P-value for outcomes: 0.002  
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Table 4.5. Most variably expressed networks between different stages of prostate cancer. 
 
Variably expressed networks (PT vs. NP) 
Network name Num. genes Num. gene pairsa Template differenceb Apparent accuracy P-value 
KERATINOCYTE 46 1035 0.070 0.981 < 1.0E-07 
TOLL 31 465 0.073 0.945 1.21E-05 
MAPK 83 3403 0.064 0.941 2.02E-05 
MET 35 595 0.103 0.941 2.02E-05 
FCER1 36 630 0.059 0.931 6.85E-05 
INTEGRIN 34 561 0.094 0.923 1.21E-04 
AT1R 34 561 0.096 0.922 1.25E-04 
ERK 29 406 0.037 0.921 1.29E-04 
CARDIACEGF 17 136 0.118 0.920 1.33E-04 
IL1R 28 378 0.071 0.915 1.81E-04 
Variably expressed networks (MT vs. NP) 
Network name Num. genes Num. gene pairs Template difference Apparent accuracy P-value 
MAPK 83 3403 0.111 1.000 < 1.0E-07 
DEATH 29 406 0.128 1.000 < 1.0E-07 
IL2RB 35 595 0.096 1.000 < 1.0E-07 
HIVNEF 53 1378 0.148 1.000 < 1.0E-07 
MET 35 595 0.165 1.000 < 1.0E-07 
NO1 27 351 0.125 1.000 < 1.0E-07 
NFAT 47 1081 0.164 1.000 < 1.0E-07 
PPARA 50 1225 0.100 1.000 < 1.0E-07 
ACTINY 19 171 0.123 1.000 < 1.0E-07 
FCER1 36 630 0.111 0.990 < 1.0E-07 
Variably expressed networks (MT vs. PT) 
Network name Num. genes Num. gene pairs Template difference Apparent accuracy P-value 
FCER1 36 630 0.119 0.985 < 1.0E-07 
TCR 44 946 0.103 0.969 < 1.0E-07 
BCR 33 528 0.133 0.969 < 1.0E-07 
HIVNEF 53 1378 0.119 0.969 < 1.0E-07 
MET 35 595 0.126 0.969 < 1.0E-07 
PDGF 27 351 0.128 0.957 < 1.0E-07 
BIOPEPTIDES 37 666 0.107 0.957 < 1.0E-07 
MAPK 83 3403 0.100 0.954 < 1.0E-07 
IL2RB 35 595 0.087 0.954 < 1.0E-07 
AT1R 34 561 0.111 0.954 < 1.0E-07 
 
aThe number of gene pairs is equal to Gm(Gm – 1)/2, where Gm is the number of genes in the network. 
bThe template difference represents the Hamming distance between two binary rank template vectors. 
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Chapter 5: Exploration of Gene Expression Analysis Methods and Applications in Cancer 
and the Brain5 
 
Results from DIRAC provide a coarse, but meaningful glimpse into patterns of network regulation for 
different phenotypes, based on combinatorial relationships between the involved genes. As such, this 
method can be a powerful first step towards characterizing network-level expression differences in new 
disease data. One interesting application has been investigating the molecular patterns that underlie 
differences in aggression of human astrocytomas. Working with fellow graduate student, Chunjing Wang, 
I have found striking correlations between dysregulation in biological pathways at the gene expression 
level and the up- or down-regulation of individual genes that may contribute to genetic heterogeneity. 
Despite these observations of high variability in astrocytomas—most prominent in the highest grades—
we were also able to ascertain robust network signatures to distinguish between grades. These findings 
present interesting hypotheses that, upon further exploration, could produce new insights into 
pathological mechanisms that give rise to different tumor grades. 
 
In this chapter, I present several other applications and extensions of DIRAC, along with alternative 
methods to explore gene expression in disease and biology. Importantly, DIRAC is not limited to disease 
applications, nor is it the only method worth considering for disease classification. As part of another 
fascinating collaborative project, I used DIRAC to examine the expression of modules in a transcriptional 
regulatory network model we reconstructed for the honeybee brain [288]. We found that several 
regulatory modules (i.e., target genes controlled by the same transcription factor) exhibited significant 
differential expression between behavioral states. These studies highlight some of the insights that can be 
gleaned through systems analysis of high-throughput data, coupled with deep domain expertise. 
 
The promising results observed with DIRAC also highlight several paths for modification and potential 
improvement of the method. In particular, the a priori defined networks used as inputs to DIRAC might 
often not be reflective of the active molecular processes in a particular phenotype. Preliminary studies 
with protein-protein interaction networks have illustrated the potential of adaptively learning context-
specific networks with DIRAC. Additionally, efforts have begun to use DIRAC for multi-class 
                                                     
5 This chapter includes material that was reproduced with permission from the following publications:  
(i) Chandrasekaran, S., S.A. Ament, J.A. Eddy, S.L. Rodriguez-Zas, B.R. Schatz, N.D. Price, and G.E. Robinson. 
2011. Behavior-specific changes in transcriptional modules lead to distinct and predictable neurogenomic states. 
Proceedings of the National Academy of Sciences USA. 108(44):18020-18025. (Network Analysis of 
Transcriptionally Regulated Modules in the Honeybee Brain section; text written in collaboration with Sriram 
Chandrasekaran and Seth Ament, analysis contributions stated in section). 
(ii) Ko Y., S.A. Ament, J.A. Eddy, J. Caballero, J.C. Earls, L. Hood, and N.D. Price. 2013. Cell type-specific genes 
show striking and distinct patterns of spatial expression in the mouse brain. Proceedings of the National Academy of 
Sciences USA. 110(8):3095-3100. (Spatial Expression Patterns in the Mouse Brain section; text written in 
collaboration with Younhee Ko and Seth Ament, analysis contributions stated in section). 
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classification problems and also to make method tools more widely accessible to the scientific 
community. Finally, DIRAC does not immediately provide insight into the higher-level interactions 
between multiple networks that may be important in disease. I have helped to develop an alternative 
approach called GSERA, which quantifies patterns among two or more biological networks.  
 
Importantly, expression analysis that focuses on patterns of individual genes can still be informative, 
especially when opportunities arise to interface with biology and medical experts, thereby providing 
valuable context to computational results. For example, a collaborative exploration of mesenchymal-to-
endothelial reverting transitions in leiomyosarcomas resulted in mechanistic and prognostic insights, 
based on the expression of informative marker genes [289]. Applying statistical and clustering 
approaches, I found that patients classified as more “endothelial-like” (based on up-regulated expression 
of marker genes) exhibited poorer survival outcomes, relative to the “mesenchymal-like” samples.  
 
 
Network Analysis of Transcriptionally Regulated Modules in the Honeybee Brain 
 
Both genotype and the environment influence behavior, and these effects lead to massive changes in the 
brain transcriptome [290]. This has led to the idea that distinct neurogenomic states underlie distinct 
behaviors, but it is not known how these states are defined and maintained. Using brain transcriptomic 
profiles from 853 individual honeybees exhibiting different behavioral phenotypes in naturalistic 
contexts, fellow graduate students Sriram Chandrasekaran and Seth Ament and I investigated whether 
behavior-specific neurogenomic states can be inferred from the coordinated action of transcription factors 
(TFs) and their predicted target genes. Our data comprised transcript profiles from 27 integrated pair-wise 
comparisons that probed hereditary and environmental influences on social behavior and brain gene 
expression. Each comparison surveyed transcriptome responses to a heritable or environmental factor 
related to one or more of three ecologically important behavioral categories: aggression, maturation, and 
foraging. Unsupervised hierarchical clustering of these transcriptomic profiles showed three clusters of 
profiles that correspond to these categories.  
 
Transcriptional regulatory network construction overview 
 
To explore the mechanisms potentially regulating these behavior-specific neurogenomic states, a brain 
Transcriptional Regulatory Network (TRN) model was reconstructed by Sriram Chandrasekaran. TRN 
reconstruction was performed using a new combination of two well-known algorithms: a network of high-
confidence putative TF-gene interactions was generated using ARACNE (Accurate Reconstruction of 
Cellular Networks [291]), and these interactions were leveraged to predict expression in new conditions 
with LARS (Least Angle Regression [292]). Interactions were inferred from expression profiles and a list 
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of 236 predicted bee TFs based on orthology with Drosophila melanogaster. The goal was to infer 
relationships between genes and subsequently predict changes in the expression of those genes involved 
in behavior in the bee brain given the expression values of the TFs. 
 
The TRN model quantitatively predicts gene expression changes of more than 2,000 genes involved in 
behavior with high accuracy, even for behavioral phenotypes on which it was not trained. Having 
demonstrated predictive ability and biological relevance, we analyzed the TRN to explore the hypothesis 
that behaviorally related neurogenomic states arise, in part, from the coordinated action of TFs and their 
predicted target genes. Most of the top 20 most connected TFs (“hubs”) and many of their predicted 
targets were differentially expressed (FDR < 0.05) across many of the 27 comparisons. Some TFs and 
their modules of putative target genes were active across all three behavioral categories (“global 
regulators”), i.e., their predicted target genes were significantly over-represented among differentially 
expressed genes across all three behavioral categories. Other TFs and their modules were active only for a 
particular behavioral state within a category. State-specific TFs were significantly more common than 
predicted by chance (P < 1e-10), indicating that they also are a robust feature of this TRN.  
 
Differential rank conservation analysis of the network 
 
I used Differential Rank Conservation (DIRAC) [293] to investigate changes in relative gene expression 
within each module, either across individual bees within states, or between states. Specifically, DIRAC 
quantifies and assesses expression consistency in the context of the rankings of target genes within a 
selected module: for each microarray, the expression values of the module genes are ordered from highest 
expression (ranked first) to lowest expression (ranked last). For any state or comparison in which genes of 
a particular module were not expressed, this module was omitted from DIRAC calculations. Two 
intriguing dynamic properties of the TRN were detected. First, while modules generally showed 
consistent gene expression across individuals within behavioral states, some modules exhibited significant 
changes in relative gene expression ordering between states.  
 
I first used DIRAC to characterize the consistency of rank ordering within each module for the individual 
bees within each of the 48 states, as detailed in [293]. A network is considered tightly regulated within a 
state if the relative expression of module genes is mostly consistent across individuals; a network is 
considered loosely regulated if the relative expression of genes is greatly varied between individuals of a 
state. Consistency of relative expression for a module in a selected state can range between 0.5 (relative 
expression of module genes is completely different in each individual) and 1.0 (relative expression of 
modules genes is identical in all individuals); the average consistency of all network modules across all 
states was 0.89±0.06, indicating that modules are tightly regulated in general within states (Figure 5.1).  
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I next used DIRAC to detect changes in relative expression of genes between states for each module. 
DIRAC identifies variably expressed or “shuffled” modules that, for each comparison, enable statistically 
significant classification of expression profiles between states [293]. I estimated P-value and FDR for 
classification accuracies by repeatedly performing calculations for each comparison with 10,000 sets of 
randomly permuted individuals. That is, DIRAC determines a probability for these “shuffling” events 
based on the accuracy with which these changes in relative gene expression can be used to classify the 
two states in the comparison. This shuffling was greatest for hub genes (Figure 5.2) such as ftz-f1, Creb, 
and Lag1, a TF linked to metabolic regulation [294]. Specifically, there was a highly significant 
association (R2 = 0.45) between the number of target genes in a module and the degree of shuffling. In 
other biological contexts, gene shuffling is associated with transcriptional “dysregulation” in diseased 
states [293]; such differences have not yet been detected in network analysis for normal states. There was 
no such association for random gene sets with the same size distribution (R2 = 0.02), indicating that this is 
a specific feature to TF-target modules, rather than an artifact of the method. 
 
Module-level expression differences at short to long timescales 
 
Changes in relative gene expression ordering also varied depending on the timescale of the underlying 
perturbation. We subdivided the 27 comparisons into three categories based on the timescales over which 
they influence behavior: long-term differences (hereditary differences between strains and sub-species 
that accumulate over evolutionary time); medium-term differences (changes occurring over a few weeks, 
primarily due to environmentally-induced changes); and short-term differences (factors that influence 
behavior for only hours or a few days; e.g., pheromones and the imprints of spatiotemporal memories on 
foraging). We compared the effects of these timescales on four aspects of network dynamics and 
regulation (Figure 5.3): the number of differentially expressed genes in the TRN (DEGs; A), the number 
of between-state perturbations in relative gene expression within modules (“shuffling”, B), the number of 
TFs influencing each target gene (in-degree; C); and the number of target genes regulated by each TF 
(out-degree; D). Statistical significance for differences between timescales was determined using Kruskal-
Wallis rank-sum tests. Increased shuffling was more often associated with longer-lasting behavioral 
states, e.g., those related to behavioral maturation, rather than more dynamic states, e.g., spatiotemporal 
floral memories (P = 0.008). Longer-lasting states also showed a significant increase in the number of 
TFs predicted to regulate each gene (P = 0.002). 
 
In other respects, the network states associated short- vs. long-term responses were quite similar. There 
were no striking differences either in the number of genes responsive to short- vs. long-term stimuli, or in 
topological properties such as the number of targets for each TF in a given context (kout); this is consistent 
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with previous findings that short- and long-term differences in honeybee aggression involve many of the 
same genes (Alaux 2009. PNAS). Together, these results suggest that both short- and long-acting stimuli 
can robustly activate genes in the network, but more stable responses frequently also involve 
perturbations in the relationships among these genes. Such regulatory complexity is considered a hallmark 
of network stability. 
 
 
Spatial Expression Patterns in the Mouse Brain 
 
To investigate the extent to which subdivisions in the mammalian brain correspond to regional differences 
in the expression of genes within major cell types, I worked with postdoctoral fellows Younhee Ko and 
Seth Ament to analyze highly spatially resolved brain gene expression data from the ABA for panels of 
cell type-specific genes. The coronal and sagittal sections were broken into small (coronal: 20um x 30um; 
sagittal: 20um x 40um) “patches” (pixels) reflecting local gene expression. K-means clustering was then 
performed (with k between 2 and 100) to find subsets of patches with similar gene expression across all 
the neuron-specific, astrocyte-specific, or oligodendrocyte-specific genes; i.e., the k-means clustering 
grouped patches based on their similarity in the cell type-specific gene expression space. For neurons, the 
clusters even up to 100 were highly spatially coordinated (Figure 5.4), though the size of the added 
regions became much smaller above ca. k = 60, which is the k I will use for a number of examples here. 
The resulting transcriptionally defined clusters were then transformed back into a color-coded brain 
image to assess their overlap with known brain regions. Our goal was to systematically characterize the 
transcriptionally distinct, spatially contiguous neuronal and glial subtypes based on their gene expression 
patterns across the brain. 
 
Investigating spatial contiguity of brain regions defined by neuron-specific expression patterns 
 
Cell type-specific genes were defined as those that were previously shown to be >10-fold enriched in 
each of these cell types. Cahoy et al. [295] found 320 genes that were >10-fold enriched in neurons, 185 
in astrocytes, and 131 in oligodendrocytes, but ABA data were available for only a subset of these genes. 
All available in situ hybridization images downloaded from the ABA showing expression on coronal or 
sagittal slices through the centermost part of the brain (1-3 images per gene on each plane). The resulting 
dataset included images for 170 neuron-, 44 oligodendrocyte-, and 50 astrocyte-specific genes for the 
coronal plane, and for 250 neuron-, 101 oligodendrocyte-, and 154 astrocyte-specific genes for the sagittal 
plane (where ABA measured more genes).  
 
After systematically quantifying the spatial patterns of neuron-specific using image processing tools in 
Matlab, I found that clusters derived from neuron-specific genes were highly spatially contiguous; i.e., 
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adjacent patches in the brain were very frequently assigned to the same cluster (Figure 5.4). For k = 60, 
59 of the 60 clusters were spatially contiguous with >59% of the patches adjacent to cluster patches 
belonging to that same cluster. All 59 of these spatially contiguous clusters had significantly greater (P < 
0.001) contiguity by this measure than I found in a distribution generated from randomly permuting the 
spatial coordinates for the patches within the mouse brain (while keeping the same number of patches per 
cluster). Known brain regions are spatially contiguous within the brain. As such, the high levels of spatial 
contiguity we observed for k-means clusters suggests that the vast majority of these transcriptionally 
defined regions correspond to functionally relevant brain regions, even with high numbers of clusters. 
 
Characterizing network-level differences between spatial regions 
 
I also used DIRAC [293] to evaluate cluster-specific differences in the relative expression levels of genes 
within functionally-related categories (defined by GO). Such “shuffled” pathways may be differently 
regulated in different parts of the brain (Figure 5.5). Intriguingly, DIRAC analysis showed that the k-
means cluster for striatum differed from the clusters for the pallidum, thalamus, and hypothalamus in the 
relative expression levels for genes involved in central nervous system development. The clusters 
corresponding to the pallidum vs. thalamus/hypothalamus could then be further distinguished by changes 
in the expression of genes related to synaptic transmission. These data are consistent with the idea that 
neurons in different regions of the brain exhibit distinct states (encoding different functions), specified by 
a multiplicity of transcripts, and that there are quite a large number of distinct neuronal states. Thus, the 
relative expression difference amongst a broad range of neuron-specific genes is the main contributor to 
the observed spatially contiguous, transcriptionally defined clusters. 
 
 
Extensions of DIRAC and Alternative Network Expression Approaches 
 
In addition to the initial version of DIRAC, I have explored an extension to the method that will add key 
functionality for dealing with mechanistic reaction networks such as the cancer-specific metabolic 
reconstruction described in Chapter 6. Prior to DIRAC, I also worked on a related project that focused on 
investigating informative patterns of expression between multiple related networks. Notably, I 
collaborated with another graduate student, John Earls, to develop a software package—Adaptive Unified 
Relative Expression Analysis (AUREA)—that includes all published forms of relative expression analysis 
algorithms for classification of gene expression profiles [246]. AUREA provides a user-friendly interface 
for employing each algorithm, as well as an adaptive learner that searches for an optimal model and set of 
parameters for classification. While the current version of AUREA includes the classification aspect of 
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DIRAC, future versions will also include population-level analyses as well as the extensions and related 
tools described below.  
 
Adaptive interaction-network based DIRAC 
 
I have developed an extension to DIRAC that offers two potentially advantageous features: (i) instead of 
a priori defined database networks, the method instead operates on specific regions (subnetworks) within 
protein-protein interaction (PPI) networks generated by high-throughput data; (ii) based on the links 
between genes in the PPI network, the method is able to adaptively grow and shrink networks to identify 
more discriminative signatures for classification. 
 
Defining subnetworks using link communities 
 
PPI information was obtained from public, manually curated databases including the Biological General 
Repository for Interaction Datasets (BioGRID), the Human Protein Reference Database (HPRD), and the 
Database of Interacting Proteins (DIP), and used to construct PPI networks. These PPI networks serve as 
inputs to the computational analyses used here. Link Communities is a hierarchical clustering method 
based on the similarity of links rather than nodes in the graph [296]. In the resulting dendrogram, nodes 
may occupy multiple agglomerations due to their links; this is important because it allows genes to be 
grouped into multiple subnetworks. 
 
Adaptive modification of variably expressed subnetworks 
 
The initial pool of networks used as the search space DIRAC may not yield the best signatures for 
distinguishing between two phenotypes. Networks defined a priori in pathway databases—regardless of 
the level of curation—may not be representative of functioning sets of genes in a particular phenotype, 
and therefore would be unlikely to serve as accurate classifiers. While interaction networks represent 
mechanistic links between genes, they may also not be specific to the phenotypes being studied; 
furthermore, subnetworks defined according to network structure may not necessarily correspond to 
informative differential expression of genes. I have used a sequential forward floating search algorithm 
[297] to grow and shrink subnetworks identified as variably expressed, in an effort to improve 
classification accuracy. 
 
The inputs to the sequential forward floating search (SFFS) algorithm are the top kth (as determined by 
apparent accuracy) link community (LC) sets. Generally, I set k to be 50. While the link communities 
were defined by utilizing PPI data, it is assumed that there is still useful information content within the 
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PPI data that has not been captured by the initial link communities. That is, the biomolecular networks 
defined by the LC sets should be refined to improve biomarker fidelity. 
 
Therefore, the sequential forward floating search seeks to adapt each LC set by iteratively adding and 
removing genes. The pool of available genes to add during an iteration is the set of genes which share an 
edge (putative interaction) in the global PPI graph with at least one of the genes already in the seed set. 
Furthermore, on each iteration, following adding the “best” gene (as determined by apparent accuracy), 
SFFS begins conditional exclusion of genes already within the set. This is in hopes of constructing the 
smallest set which still provides the best accuracy. Imagine a set of genes {a,b,c,d} to which is added 
gene e. Gene e provides all of the information (in the sense of acting as a distinguishing biomarker for 
phenotypes x versus y) already provided by gene b, and then some. Thus, SFFS would be able to safely 
remove gene b. If instead the best gene to remove would be that just added on this iteration, gene e, then 
SFFS removes no genes and goes on to the next iteration. The conditional exclusion step proceeds as long 
as possible in a given iteration, and thus on a single SFFS iteration, exactly one gene may be added, but 
zero or more genes may be removed. 
 
Classification results for disease datasets 
 
The adaptive version of DIRAC was used to classify all datasets from the original DIRAC publication. I 
compared results with and without the adaptive search, using both BioCarta signaling pathways and PPI 
link communities as starting network inputs. Overall, I found little difference in the performance of 
DIRAC with any particular set of parameters—some scenarios improved accuracies for particular 
datasets, but performed less well on other datasets. One possible limitation of this approach could be in 
the reliability of interactions in the PPI—i.e., any false positive interactions in the network may create 
additional noise rather than adding biological context. An alternative approach that I plan to explore is to 
use more carefully curated biochemical networks such as pathways in a metabolic reconstruction as input 
to the algorithm. 
 
Pathway expression analysis with GSERA 
 
A common feature of existing network analysis methods is a focus on individual networks—independent 
of other networks in the cell—and how they change between phenotypic states. However, researchers 
have frequently observed that multiple networks are perturbed in cancer cells [39, 43, 298, 299]. As 
studying interconnected or related genes on the network level can be highly informative for elucidating 
functional change in diseased cells, analyzing the combinatorial behavior of multiple related networks 
may lead to further biological insight. We can easily extend network analysis methods to address this 
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problem: by defining a measure of overall expression for a network, we can apply existing algorithms to 
“networks of networks,” analogous to the more common networks comprised of participating genes. I 
previously developed an approach called Gene Set Expression Reversal Analysis (GSERA) to identify 
molecular signatures comprising multiple related networks. RXA refers to a class of algorithms that 
assess the ordering among gene expression values, rather than their absolute expression values (reviewed 
in Eddy et al. [300] and in Chapter 3); one searches for characteristic perturbations in this ordering from 
one phenotype to another, or within phenotypes. In particular, GSERA adapts the top-scoring pair (TSP) 
algorithm to study network families in disease.  
 
GSERA is a pathway based analysis method that combines gene expression measurement over groups of 
genes that fall within common pathways for a more effective marker discovery. The pathways used were 
a priori defined and drawn from Gene Ontology [81] and KEGG [80] databases. The approach is based 
on the top scoring method [243] and extends mRNA expression level comparisons to comparisons of 
expression levels of pathways or gene sets between different disease classes. It can be applied for disease 
class prediction as well as identifying the biological signatures actuating disease progression. The method 
involves pathway aggregates of genes and only relative expression values. GSERA was used to study 
various cancer and non-cancer datasets including Parkinson’s disease, prostate cancer, breast cancer, 
Marfan syndrome, bipolar disorder, an airway transcriptome dataset, and GIST & LMS tumors.  
 
Calculating Gene set Expression Values  
 
GSERA considers the experiment sets where gene expression profiles of several (on the order of 
thousands) individual genes are described for samples belonging to different phenotypic classes. These 
expression profiles are converted from being those for individual genes to the corresponding values for 
sets of genes or pathways. Thus, GSERA analysis begins with the calculation of gene set expression 
values from the gene expression values provided by microarray data. Various methods have been 
previously described for calculation of these gene set values given gene expression data. For ease of 
calculation and comparison with other such studies, in this study gene set expression values were 
calculated by taking the average of all gene expression values in a gene set. In addition to mean 
expression, other summary metrics such as median expression were also used to quantify gene set 
expression; no metric was optimal in all cases. 
 
The gene set definitions, which describe the constituent “n” genes of each gene set were obtained from 
public databases. These definitions group genes based on their positions on a chromosome (positional 
gene sets), on their participation in pathways (biochemical, signaling, or regulatory) as defined in 
literature (curated gene sets), or as belonging to the same GO term in the Gene Ontology initiative (GO 
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gene set). The available Matlab implementation of the GSERA program allows use of each of these 
diverse gene set definitions and additional gene to gene set expression value conversion metrics. 
 
Classification with and Limitations of GSERA 
 
Being a gene-set expression value analysis, GSERA focuses on identifying biologically and statistically 
significant pathways and processes and exploits the inherent modular structure of biological networks to 
reveal network changes that accompany a disease process. The GSERA method was tested on different 
datasets using three different sets of a priori defined pathways. The estimated prediction rate of the 
classifier for each study was also compared to TSP, DIRAC, and SVM classifiers. In general, the method 
did not lead to significant improvement in classification accuracy compared to other algorithms. 
 
A potential limitation of the method arises because although completely sequenced, the functional 
annotation of genes in the human genome is still an ongoing process. Due to this, current pathway 
definitions available are not completely representative of the biological system. Information gathered by 
microarray experiments is also not completely utilized due to this lack of complete annotation of all 
probes used on the array. Another difficulty faced by research groups analyzing gene expression data 
using pathway based methods is the lack of a universal annotation system for genes and pathways. In 
addition to typically unremarkable gains in classification compared to other tools, the relationships 
between pairs of pathways found by GSERA are often unclear. Restricting the search to biological 
processes connected in the gene ontology structure helps provide more tractable results, but both GO 
relationships and the terms themselves vary greatly in terms of reliability and interpretability.  
 
Finally, and perhaps most importantly, the use of summary statistics such as mean or median to quantify 
the activity of multiple genes in a single pathway is far from ideal. For example, the expression level of a 
pathway could be easily skewed by very high or low expression of one or a few genes. The solution to 
this problem is not immediately obvious, but may involve using measures more closely tied to network-
level functioning (such as metabolic fluxes). Still, examining the relationships between multiple gene 
sets—and how these relationships change in disease—remains a problem of great interest, and the general 
scheme of GSERA may provide useful in future studies. 
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Chapter 5 Figures 
 
 
 
Figure 5.1. Within-state consistency in the relative expression of target genes within each 
module. Rows correspond to each TF and columns are the various pairwise comparisons. 
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Figure 5.2. Between-state reordering of relative gene expression increases with module size.  
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Figure 5.3. Factors that influence behavior over long vs. short timescales influence network 
states differently. 
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Figure 5.4. Spatial contiguity and size distribution of k-means clusters for neuron-specific 
genes at large k. 
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Figure 5.5. Clusters corresponding to major subdivisions in the mammalian brain are 
characterized by expression differences for individual marker genes and reordering of 
functionally related gene sets. 
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n = 12 genes*, Accuracy = 89%***
n = 6 genes, Accuracy = 74%***
n = 12 genes, Accuracy = 64%***
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Chapter 6. Evidence-driven reconstruction of a glioblastoma metabolic network: a 
platform for data integration and in silico investigation6 
 
Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor. 
Classified as grade IV astrocytoma, GBM develops from astrocytes (glial cells) and presents a median 
survival rate of about 15 months, even with surgery followed by radiation or chemotherapy. Importantly, 
perturbations to cellular networks in GBM eventually result in the symptoms of disease observed by the 
patient, including seizure, nausea, vomiting, headache, and a progressive deterioration of memory and 
personality. These phenotypes arise not from any single mutation, but from the sum effect of complex 
interactions among multiple aberrant genes and other molecular agents. The combinatorial nature of GBM 
tumor development therefore mandates a systems-level approach to elucidate underlying mechanisms of 
the cancer. 
 
Cancer is particularly amenable to systems biology approaches because it is an intrinsically complex and 
heterogeneous disease [301]. The convolution of genetic effects, changes in gene and protein expression 
levels, and epigenetic modifications that give rise to malignancies like GBM further illustrates the 
complex, nonlinear relationship between molecular state and cellular cancer phenotype. Efforts in 
sequencing the human genome [302, 303] and individual cancers [39, 40] have made it increasingly clear 
that GBM and other cancers result not only from multiple perturbations, but from differing sets of 
mutations in every patient [39]. Such a distribution of mutations presents enormous challenges for 
personalized medicine, because it means that simple mutation to treatment correlations are not likely to be 
effective. Reconstructing detailed in silico models of biochemical reaction networks (e.g., metabolic, 
signaling, regulatory) at the genome scale establishes a platform on which different genetic perturbations 
can be related to emergent malignant functions and phenotypes. 
 
Metabolism is arguably the best understood cellular process and is highly perturbed in oncogenesis, 
where cancer cells have increased metabolic rate to provide the energy needed for increased proliferation 
[41-43]. Thus, metabolism provides an ideal setting to begin reconstructing detailed biochemical 
networks at the genome-scale for GBM. Metabolite-based analyses to probe cancer have been performed 
since the 1980s [44] and have shown that cancer cells display distinct metabolic profiles, which can be 
characterized to diagnose the type and progression of disease, inform prognosis, and assess efficacy of 
therapy [45]. Metabolic phenotypes that remain consistent across cancer types, including GBM, reflect 
                                                     
6 This chapter includes material that was reproduced with permission from the following publication:  
Wang, Y., J.A. Eddy, and N.D. Price. 2012. Reconstruction of genome-scale metabolic models for 126 human 
tissues using mCADRE. BMC Systems Biology. 6:153. (Metabolic Context-specificity Assessed by Deterministic 
Reaction Evaluation (mCADRE) section; methods, results, and text generated in collaboration with Yuliang Wang). 
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decreased aerobic respiration activity [46, 47] coupled with increased glycolysis [45, 46] and increased 
phospholipid production [46, 48]. These observations have led to targeted diagnosis and treatment 
strategies [45, 49]. In addition to broad spectrum cancer markers, metabolite signatures specific to 
astrocytomas have been found [304], which can be used to distinguish astrocytomas from other brain 
cancers.  
 
Utilizing the recently published generic human metabolic reconstruction—a well-curated repository of 
reaction information—I have computationally integrated gene and protein expression data from multiple 
sources to define a network specific to GBM. Specifically, to generate a cell-type specific metabolic 
network for the U87 MG cell line, I used a collection of gene and protein expression evidence with an 
updated implementation of the mCADRE tool I co-developed. This tool is designed to weigh evidence 
and network connectivity in order to deterministically rank reactions in a generic (i.e., non-specific) 
metabolic model, prior to sequentially pruning the lowest ranked reactions from the network. Just as I 
have used mCADRE to generate the GBM-specific model, mCADRE can be used with other forms of 
gene or protein expression data to create cell- and tissue-specific metabolic models for other disease 
models. This can greatly aid in identifying areas of interest for experimental exploration and/or validation.  
 
From this cell line-specific model, one is then able to model metabolic flux through an approach known 
as constraint-based modeling. Constraint-based modeling with the GBM network allows for simulation of 
cell growth under physiologically relevant conditions and investigation of mechanisms for tumor 
development. Curated pathways in the reconstructed network also provide functional context for 
statistical approaches to study gene expression in disease states. These combined approaches enable the 
identification and detailed characterization of key perturbed pathways in GBM.  
 
 
Tissue-specific Metabolic Model Reconstruction Methods 
 
While the need for tissue and cell type (henceforth referred to as context) specific metabolic models is 
strong, the number of such models is small. Manual curation often takes more than one person-year to 
produce a functional model [305], limiting the ability to produce a large number of context-specific 
functional metabolic models. Therefore, computational methods are clearly needed to speed up the model 
building process. The current state-of-the-art computational method to build context-specific models, the 
Model Building Algorithm (MBA) has been used to build metabolic models for liver, generic cancer, and 
two cancer cell lines [306-308]. However, the high computational cost/complexity involved with this 
method limits the ability to go through iterative rounds of model building and curation, which is typically 
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done in manual reconstruction of metabolic models [305]. It also limits the ability to build metabolic 
models for each individual tissue and cell types in an organ as complex as the brain.  
 
Model Building Algorithm (MBA) 
 
I initially explored using MBA, as described in Jerby et al. [306], to systematically prune reactions from 
the generic Human Recon 1, leaving a tissue- or cell-type-specific network. Given expression evidence 
specific to the cell type of interest, one first defines two core sets of reactions: high confidence reactions 
in tissue core 1 (TC1) and moderate confidence reactions in tissue core 2 (TC2); each core is a subset of 
the full list of reactions in Recon 1. The objective of MBA is to maximize the number of reactions 
included from TC2 while minimizing the inclusion of non-core reactions, subject to the requirements that 
all reactions in TC1 are consistent (i.e., can carry non-zero flux in at least one condition). 
 
I developed a Matlab implementation of MBA that offers two convenient features: integration with the 
COBRA toolbox and optional use of fastFVA. The COBRA (Constraint-Based Reconstruction and 
Analysis) toolbox provides a suite of tools for constructing, curating, simulating, and analyzing metabolic 
network models in Matlab. To take advantage of the efficient and user-friendly features of the COBRA, I 
have written this version of MBA to utilize built-in functions for model parsing, organization, and 
optimization. I have also added an optional feature that significantly increases computational performance 
relative to a direct translation of the published MBA algorithm to Matlab. Specifically, the original 
version of MBA uses a heuristic optimization approach to evaluate the consistency of core reactions (see 
Jerby et al. for a detailed description of the checkModelConsistency module), reducing the number of 
iterations needed for the flux variability analysis (FVA) algorithm, and dramatically speeding up this step. 
Because FVA is still needed for the majority of calculations in the consistency check, this represents a 
substantial bottleneck in computational time. To further speed up the checkModelConsistency component 
of MBA, I have included the option to perform all remaining FVA iterations with the fastFVA algorithm; 
fastFVA was developed by Gudmunsson et al. [309], and has been demonstrated to improve performance 
of FVA by 30 to 220 fold. 
 
Metabolic Context-specificity Assessed by Deterministic Reaction Evaluation (mCADRE) 
 
Taking advantage of the Matlab implementation of MBA, my fellow graduate student, Yuliang Wang, 
and I recently developed a new method called metabolic Context-specificity Assessed by Deterministic 
Reaction Evaluation (mCADRE) (Figure 6.1), which achieves dramatic computational speed up by 
deterministically ranking all reactions based on gene expression data and metabolic network topology 
[310]. This deterministic decision-making in mCADRE, coupled with an automated pipeline of data 
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collection and processing, enables researchers to efficiently generate accurate and robust initial models 
from publicly available expression data (Figure 6.1). We used mCADRE to build a normal liver model 
and compared this model with the liver model built with MBA in the original publication [306]. 
mCADRE achieves dramatic computational speed up compared to MBA, and mCADRE models have 
better functionality compared to MBA models based on the same input data. The improvements afforded 
by mCADRE enable both iterative computational model curation as new high throughput data or 
literature evidence become available, and the reconstruction of metabolic models for a large number of 
different tissues and cell types. 
 
 
Curating Human Recon 2 and Evidence-based GBM Model Construction  
 
To generate a cell-type specific metabolic network for the U87 MG cell line, I used a collection of gene 
and protein expression evidence with an updated implementation of our mCADRE tool (Figure 6.2). This 
tool is designed to weigh evidence and network connectivity in order to deterministically rank reactions in 
a generic (i.e., non-specific) metabolic model, prior to sequentially pruning the lowest ranked reactions 
from the network. The original implementation of mCADRE prohibits removal of any reactions that 
prevent the production of certain precursor metabolites from a single carbon substrate (i.e., glucose). 
Here, I assumed that cellular growth is a valid objective for the U87 cancer cells, and therefore imposed a 
requirement for biomass production given a defined medium. In other words, reactions could not be 
removed from the generic model if this action prevented cell growth. 
 
Several preliminary steps were necessary to enable this approach, including collection of expression 
evidence, literature-based definition of the U87 biomass composition, modification of the generic model 
(i.e., Human Recon 2), and updating the mCADRE algorithm. The updated version of Recon 2 described 
here represents only minor changes to the overall network composition along with expansion of meta-
information such as alternate database identifiers for metabolites and reactions. As such, these 
incremental changes do not substantiate a new version of the master SBML file, but code is available to 
automatically recreate all steps for creating Recon 2.01. 
 
Curation and priming of Human Recon 2 
 
Requiring the cell-type specific U87 model to be capable of growth at all stages of network pruning 
mandated that the generic model be a priori capable of growth. While the Human Recon 2 model 
extracted from the published SBML file can produce biomass “out of the box,” the large number of 
metabolites that are allowed to freely exchange into and out of the cell are not reflective of relevant in 
vitro conditions. When this excessively rich medium was replaced with a more minimal defined medium 
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(comprising essential amino acids, essential fatty acids, glucose, and several other carbon-free and 
carbon-containing vitamins and minerals), however, growth could no longer be achieved. I identified 
specific components of the biomass equation that could not be produced, and traced back along their 
potential production routes to identify three specific deficiencies in the network: 
 
i. De novo production of NAD from tryptophan 
ii. Mitochondrial synthesis of NADP from NAD 
iii. Synthesis of fatty acyl “R” groups for lumped lipid synthesis pathways 
 
These issues were addressed as follows. (i) I identified the nicotinate-nucleotide diphosphorylase 
(NNDPR) reaction, previously included in Human Recon 1, which catalyzes the conversion of quinolinate 
and 5-phosphoribosyl diphosphate to nicotinate D-ribonucleotide. This reaction represents an essential 
step in the pathway from tryptophan (an essential amino acid) to NAD, and was previously annotated 
with the gene 23474. Without any clear indication of why this reaction had been removed, I added 
NNDPR to Recon 2 with the previous meta-information. (ii) I identified a recent study reporting the 
isolation of a mitochondrial NAD kinase (encoded by the gene 133686). Based on this finding, NADKm 
was added to Recon 2 with stoichiometry that mirrors the cytosolic NADK. (iii) Several reactions 
required for the ultimate synthesis of lipid biomass components from selected shorter-chain fatty acids 
were originally set to zero upper and lower bounds in Recon 2, effectively preventing any flux through 
these reactions.   
 
Additionally, when pruning the modified version of Recon 2 to a U87-specific network, I viewed the 
production of a more relevant U87 biomass composition to be a more suitable requirement than the built-
in generic biomass definition. As such, I examined several published experimental studies to modify the 
overall fractional composition of macromolecules in a unit of biomass (gram of dry weight) as well as the 
specific distribution of key metabolites within each class of macromolecule. This U87 biomass reaction 
was added to Recon 2.01, along with two additional transport reactions required for the production of 
glycogen and ganglioside GM1, respectively, prior to pruning with mCADRE. 
 
Collection of publicly available U87-specific expression evidence 
 
Tissue-specific and cell-type specific expression data was obtained primarily from the Human Protein 
Atlas (HPA) and the Gene Expression Omnibus (GEO). As gene expression is often poorly correlated 
with protein expression—and by extension, enzyme activity—I have placed stronger evidence on direct 
protein expression measurements as evidence for the network reconstruction (defined below). The HPA 
contains protein expression measures for three different GBM cell lines: U138MG, U251MG, and U87 
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MG, as well as normal and cancer tissue samples from glial cells and malignant gliomas, respectively. 
Due to the lack of specificity in tissue sample expression data (no distinction between astrocytes, 
oligodendrocytes, etc.), I have chosen to focus on GBM cell line data thus far to drive the reconstruction 
of the metabolic network; gene expression data is likewise sparse and unspecific for normal or healthy 
glial cells. 
 
For the U87 cell line, I generated a union list of proteins, combining those with evidence of strong 
expression in HPA, and those with evidence of moderate expression. A protein is designated as strongly 
or moderately expressed in a cell line based on evidence from immunohistochemistry, 
immunofluorescence, Western blot, or protein array. To control for quality, I kept only those proteins 
achieving a supportive validation score (as opposed to uncertain or not supportive) for at least one 
evidence type. As protein lists on HPA are reported as HTML tables for manual inspection only, I 
developed a Python-based module to enable rapid acquisition of expression evidence for a tissue or cell of 
interest. Protein expression evidence was mapped to genes in Recon 2 based on NCBI gene ID. To 
supplement the protein expression evidence obtained from HPA, I compiled datasets from GEO with gene 
expression profiles for U87 samples.  
 
Updating mCADRE to account for multiple sources of expression evidence 
 
After Recon 2 had been effectively primed as the starting point for mCADRE, I used three sources of 
evidence to rank the context-specificity of model reactions. First, I used raw Affymetrix microarray data 
for wildtype U87 cell lines from GEO. Using the MAS5 call, I binarized gene expression in this dataset as 
“expressed” or “not expressed.” From the binarized data, I calculated “ubiquity” scores for each gene 
indicating the prevalence of expression across all samples. These ubiquity scores represent the primary 
scale by which reactions are ranked in mCADRE. Second, I used RNA-seq gene expression data for 
wildtype U87 cell lines in multiple conditions. If ubiquity scores for any genes among the RNA-seq data 
were higher than in the microarray data, the former values was used. Finally, I referenced lists of high and 
moderately staining proteins in U87 cells from HPA. Given the relatively weak link between gene 
expression and enzyme function in a metabolic network, I placed greater weight on protein expression 
when ranking reactions. Any gene for which there was corresponding protein expression evidence in HPA 
was automatically assigned a perfect ubiquity score; this ensured that the associated reaction would be 
included in the high-confidence core prior to pruning in mCADRE. 
 
Generation of a genome-scale model of the U87 MG GBM cell line 
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After running mCADRE, the pruned model contained 3,058 reactions and 2,032 metabolites. Notably, an 
initial step of processing and ranking of reactions in mCADRE involves removal of all blocked reactions 
(2,836 total); our gene and protein expression data suggested strong evidence for 919 of these reactions, 
and these were added back to the pruned model. The final U87-specific metabolic model includes 3,977 
genes and 3,274 metabolites corresponding to 1,583 genes. The 996 blocked reactions in the final model 
highlight gaps in biochemical knowledge—given that these reactions are expected to be present based on 
strong expression evidence, such gaps would be higher priority targets of future investigation and 
curation. Importantly, including these reactions and genes enables greater coverage of omics data. 
 
 
Conclusions & Future Directions 
 
Using the mechanistically detailed model I have built for the U87 GBM cell line, one can begin to 
interrogate the link between molecular changes in the cancer and key metabolic processes that contribute 
to tumorigenesis. The model also serves as a powerful tool for studying pathway-level changes in GBM 
omics measurements. In the future, systems analysis of GBM with the model should continue to provide 
important biological insights into underlying mechanisms and potential treatment routes for the disease. 
 
Notably, biologists in my lab have begun conducting experiments and generating novel high-throughput 
measurements for U87 cells under several genetic and environmental conditions. These cells and data will 
enable multiple additional steps for validating and interrogating the metabolic model. First, using the 
model, I will attempt to predict qualitative effects (increased or decreased growth, ATP production, 
oxygen consumption) of numerous inactivated reactions, based on an experimental screen of enzyme 
inhibitors in U87 cells. Importantly, incorrect predictions point to areas of the network that will need 
future refinement or that might be subject to additional layers of regulation. 
 
Second, by integrating RNA-seq and targeted metabolomics measurements from U87 cells treated with 
vehicle or EGF, we will be able to identify metabolic pathways enriched for differential expression of 
genes or metabolites in these conditions. As discussed above, networks defined a priori in pathway 
databases may not be representative of functioning sets of genes in a particular phenotype. The metabolic 
network, to be reconstructed based on evidence specific to GBM, will already divided into functional 
subnetworks—based on known biochemical pathways—that can serve as inputs to network-level analysis 
tools; these subnetworks can even be grouped into broader categories of metabolism (e.g., energy 
metabolism) to define network families. When operating on high-confidence pathways in the GBM 
metabolic network, DIRAC and GSERA should produce more robust and mechanistically relevant 
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results. In turn, perturbed pathways identified will serve as the focal point for future simulations and 
model development. 
 
Additionally, GBM was one of the first cancers studied by The Cancer Genome Atlas (TCGA), and 
remains a major focus of the program. The TCGA has collected data for several hundred GBM tumors—
including sequence, copy number, methylation, and expression data, all of which is publically available 
[299]. The distribution of mutations in GBM has been shown to differ from patient to patient. By 
examining the frequency of mutations within different biological networks, such as metabolic pathways in 
the genome-scale model, we may be able to identify functional sets of genes that are consistently altered 
in the cancer. I will map compiled mutational data onto corresponding enzymes in the GBM metabolic 
network, and apply statistical tests for enrichment or over-representation to identify key subnetworks that 
tend to be perturbed in GBM. 
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Chapter 6 Figures 
 
 
 
Figure 6.1. Schematic overview of the mCADRE algorithm for generating tissue-specific 
metabolic network models based on expression evidence and network connectivity. 
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Figure 6.2. Evidence based reconstruction of the U87 glioblastoma metabolic network. 
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Chapter 7. Conclusion 
 
Systems biology employs an integrative approach to characterize biological systems, in which 
interactions among all components in a system are described mathematically to establish a computable 
model that integrates this data into a cohesive whole. These in silico models can be simulated to 
quantitatively study the emergent behavior of a system of interacting components. Integrating 
heterogeneous dynamic data into quantitative predictive models holds great promise to significantly 
increase our ability to understand and rationally intervene in disease-perturbed biological systems. This 
promise—particularly with regards to personalized medicine and medical intervention—has motivated the 
development of new methods for systems analysis of human biology and disease. 
 
Despite the exciting potential and incremental progress made in systems biology to date, the field as a 
whole has yet to deliver particularly remarkable or transformational contributions to either health or 
industry. While this can in some ways be attributed to the monumental complexity in higher organisms 
like mice and humans, it is clear that there is a great deal we still do not understand—and are thus unable 
to effectively model—about microbial behavior as well. Ongoing efforts in model and method 
development are focused on accounting for increasing amounts of cellular complexity with more 
powerful and sophisticated approaches. On the other hand, the incredible amount of high-throughput data 
that continues to be generated in almost all areas of biological research demand ever-improving 
computational tools to integrate and make sense of these measurements. Moving forward, a key goal in 
modeling efforts will be the integration of multiple network types, which will in turn enable the 
integration, analysis, and simulation of multiple types of omics data.  
 
Constraint-based modeling is a well-established framework for linking genotype to phenotype, and 
genome-scale metabolic models have been constructed for an ever-expanding array of organisms, 
spanning all branches of life. While the potential of such models for both basic and applied science has 
been demonstrated, extensive opportunity remains for expanding this framework to incorporate and 
interpret multiple types of omics data. Successive application of a hierarchy of constraints (e.g., 
transcriptional regulatory, translational, post-translational) within an integrated theoretical framework will 
enable progress towards a comprehensive understanding of emergent properties of biological systems 
(Figure 7.1). Metabolic network models will serve as a chassis for the integration of other biochemical 
and statistical network modeling frameworks.  
 
A key aspect of many diseases—especially cancer and viral infections—is the interaction between foreign 
agents or transformed cells and various players of the host immune system. While methods for molecular 
network modeling that focus directly on the diseased systems have been highly informative, accounting 
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for the complex interplay between cancer or viruses and immune cells may reveal important new 
understanding of underlying mechanisms. Approaches to model such tissue-level interactions can 
effectively extend intracellular molecular interactions to tissue-level interactions in an unprecedented 
way. As the interplay between host and disease cells ultimately determines clinical outcome, considering 
the effects of larger scale interactions on intracellular network behavior will greatly enhance model 
predictive power.  
 
Another important consideration for future efforts in systems biology is not to just account for more 
complex and more types of data, but to establish a more rigorous understanding of model and method 
capabilities. Saccharomyces cerevisiae (baker’s yeast) is not only a model lab microorganism, industrial 
workhorse, and one of the best-characterized eukaryotes, but the extent to which its metabolic network 
has been studied, modeled, and curated is second only to that of E. coli. Yeast provides an ideal platform 
to develop and test approaches for integrated modeling and networks because (i) publically available 
high-quality datasets exist for a range of strains and conditions, and (ii) yeast utilizes regulatory 
mechanisms that are conserved across many eukaryotes, facilitating application of novel modeling 
approaches to other organisms. Lessons learned from more carefully examining, curating, and validating 
model predictions with yeast will facilitate efforts to understand more complex systems in higher 
organisms.  
 
Finally, it will remain critical to interface computational and modeling efforts with experimental work 
and domain expertise. The honeybee project (described above) to which DIRAC was applied—a 
collaborative effort with experts in insect biology and neuroscience—is also an excellent example of the 
impetus to combine computational expertise with deep biological knowledge of leading scientists. 
Similarly, I led the computational gene expression analysis component of a larger experimental study of 
cellular processes in sarcomas being conducted at the University of Texas M.D. Anderson Cancer Center. 
In both of these studies, modeling approaches provided additional powerful ways to interrogate large 
amounts of data, but biological expertise was essential for gleaning useful insights from analysis results. 
 
Ultimately, modeling efforts in systems biology should enable predictive, mechanistic interrogation of 
biomolecular networks in disease, and establish a platform for interpreting large cohorts of patient data 
with stronger functional context. Integrating heterogeneous data into these quantitative models will not 
only increase our ability to understand and rationally intervene in disease-perturbed biological systems, 
but facilitate rapid and powerful hypothesis generation to guide experiments and drive the expansion and 
refinement of biological network knowledge.  
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Chapter 7 Figures 
 
 
 
Figure 7.1. Iterative process of data incorporation and network refinement through 
integrated modeling of metabolism and hierarchical regulatory constraints. 
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